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Abstract 
The focus of this doctoral research was to investigate the long-term psychosocial and 
behavioral implications of genetic testing for and living in families with Lynch syndrome 
(LS). A primary purpose of the research was to develop a clinical monitoring tool capable 
of assessing psychosocial adjustment and conduct a psychometric evaluation of the 
Psychosocial Adjustment to Hereditary Diseases (PAHD) scale. This dissertation consists 
of five chapters including an introductory and discussion chapter. The middle three 
chapters focus on the long-term psychosocial and behavioral adjustment to LS and 
development of the PAHD. Collectively, the studies and resulting manuscripts constitute 
a thesis that forms the basis for an ongoing and future program of research for monitoring 
adjustment to hereditary diseases. 
 
Adjustment to the presence of hereditary cancer is best described as an evolving state that 
ebbs and flows in response to changing personal and family experiences in the 
management of long-term cancer risk and emergence of cancer in the self and/or others. 
The findings indicate that both carriers and non-carriers experience long-term personal 
and family challenges in living with the presence of LS. In fact, the findings suggest that 
the management of LS has implications for many individuals and families that extend 
well beyond the initial genetic testing event. The results also suggest the importance of 
personal resources and the family context in facilitating or impeding adjustment. 
Importantly, a confirmed presence of LS requires lifelong cancer screening and/or 
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surveillance to reduce morbidity and mortality. Therefore, it is crucial to assess how 
individuals and families are adjusting to hereditary cancer in the long-term. 
Psychometric testing of the PAHD scale was based on the work of Ware and Gandek 
(1998). Steeped in the experiences of those living in families with LS, the PAHD was 
found to be a psychometrically sound scale that is capable of assessing psychosocial 
adjustment. Preliminary findings support the convergent, discriminant and construct 
validity of the subscales. It is concluded that the PAHD may be a valuable monitoring 
tool to identify individuals and families who may require therapeutic interventions. 
 
The findings have implications that can be utilized to enhance the clinical management of 
individuals and families with LS. Individuals living in these families may need 
supportive interventions to effectively manage their cancer risks and minimize 
adjustment difficulties. From a policy perspective, resources are needed to enhance the 
coordination, continuity and provision of health care services that promote optimal health 
functioning and a quality of life. The familial and lifelong nature of LS necessitates long-
term resources to ensure availability and accessibility of interventions that result in 
improved health outcomes. 
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CHAPTER 1 
Introduction 
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The Human Genome Project (HGP) and rapid developments in genomic medicine have 
provided individuals with genetic risk information that can identify susceptibility to many 
health alterations. In fact, genetic predisposition has become a significant determining 
factor of chronic diseases and disability [1]. The identification of causal genes 
responsible for adult-onset diseases such as cancer, neurodegenerative disorders and heart 
disease have enabled individuals and families to determine their level of risk.  
 
Depending on the clinical trajectory of the disease, knowledge of genetic predisposition 
can offer potential benefits. It can facilitate health care decisions, motivate behavior 
change and, in some cases, individualize presymptomatic and/or prophylactic treatments 
[2]. While this new genetic knowledge can offer possibilities for health promotion and 
early interventions, it can have a lifetime of consequences for those identified as living 
“at-risk”. A confirmed genetic link to disease can bring much uncertainty to families as 
individual members face many unknowns and deal with an often unpredictable and 
evolving disease state. 
 
In recent years, ongoing gene discovery has resulted in the confirmation of various 
hereditary cancer syndromes and an increasing research base on the implications of 
having a genetic link to cancer. Living with lifelong cancer risk requires psychosocial and 
emotional adjustment as well as behavioral change. Importantly, identifying individuals 
at risk for cancer could facilitate targeted screening, health promotion and prevention 
strategies, early interventions and quality outcomes. 
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The focus of the research addressed in this dissertation is on the psychosocial and 
behavioral implications of living in families with a confirmed presence of hereditary 
cancer, specifically Lynch syndrome (LS). A primary purpose of the overall program of 
research was to develop clinical monitoring tools that are capable of assessing the impact 
of the genetic testing process and long-term psychosocial and behavioral adjustment. A 
focus of this researcher’s doctoral work was to conduct a secondary analysis of a 
qualitative data base for the purpose of identifying the psychosocial and behavioral 
implications of living in families with LS. A second focus was to develop and conduct 
preliminary testing of the Psychosocial Adjustment to Hereditary Diseases (PAHD) scale. 
 
This dissertation is presented in a manuscript format with an introductory chapter and a 
final chapter acting as bookends to the three manuscripts (chapters 2, 3, and 4).  Chapter 
1 provides the reader with an introduction to the research, including the rationale and 
background information on the program of research. It also provides an overview of the 
team’s research to date and this researcher’s role as part of the research team. Chapter 2 
presents the qualitative findings on the long-term emotional and psychosocial impact of 
LS for carriers and non-carriers. Chapter 3 details the various phases and steps involved 
in the development and preliminary testing of the PAHD scale. Chapter 4 summarizes the 
second qualitative paper on how carriers of LS experience disease management and view 
the quality of interactions with health care providers and the overall health care system. 
Chapter 5 presents a general discussion of the findings and implications for clinical 
practice, policy and research. 
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Background and Rationale 
The discovery of a genetic marker for Huntington’s disease (HD) in 1983 facilitated the 
use of linkage analysis to identify carriers and non-carriers of a genetic-based disease [3]. 
Subsequently, the identification of the gene mutation for HD in 1993 led to the 
development of genetic testing protocols within a multidisciplinary framework that 
included careful consideration of potential negative outcomes [4]. These discoveries 
prompted an expanding research base on the implications of genetic testing and living 
with knowledge of disease risk.  
 
Several authors emphasize the need to understand the long-term psychosocial, emotional 
and behavioral implications of harbouring a genetic predisposition [2,3,5]. In particular, 
health care providers must have knowledge of the complexities of living with a genetic-
based disease so that clinical practice can be informed when planning care for those 
affected [2,6]. Further, hereditary disease is a family matter with significant implications 
for all members [2,7]. It is essential to understand how families are burdened by 
hereditary disease and develop a more familial approach to genetics-based health care 
[2,8].  
 
One disease with a confirmed genetic link is colorectal cancer (CRC). As the second 
leading cause of cancer deaths in Canada, CRC is of significant concern to all Canadians. 
It is of particular interest in Newfoundland and Labrador (NL) as this province has the 
highest incidence of CRC in Canada [9,10]. In fact, the age-standardized incidence rate in 
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2010 was reported to be 138 cases per 100,000, which was 36% higher than the Canadian 
average of 102 cases per 100,000 [9]. About 95% of the NL population (517,000) can 
trace their origins to either Southeast Ireland or Southwest England, thus limiting its 
ethnic and racial diversity [10].  
 
A major form of inherited CRC is hereditary non-polyposis colorectal cancer (HNPCC). 
Families with HNPCC meet the Amsterdam criteria (Appendix A) which were originally 
devised in 1991. HNPCC is considered to be present if at least three family members in 
two generations had CRC, one affected person was a first degree relative of the other 
two, and at least one affected individual was diagnosed before 50 years of age [11]. The 
Amsterdam I criteria were revised in 1999 (Amsterdam II criteria) to include some of the 
extracolonic cancers associated with HNPCC [11]. Lynch syndrome represents a subset 
of HNPCC with most tumors evidencing microsatellite instability but molecular testing is 
required to document the presence of a DNA mismatch repair (MMR) gene mutation 
(i.e., MSH2, MLH1, MSH6, PMS2) [10,12,13]. MSH2 and MLH1 account for nearly 
50% and 40%, respectively, of the mutations associated with LS. MSH6 accounts for 7-
10% while PMS2 is found in less than 5% of the alterations [14]. The underlying gene 
defect for LS was discovered in 1993 facilitating the availability of genetic testing for 
known mutations [15]. 
 
Evidence indicates that there may be differences in cancer risks for mutation carriers 
depending on gender and the LS genotype. When compared to females, male carriers 
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with MSH2 and MLH1 mutations have a higher risk of CRC [13], a finding that is 
supported in those with a MSH2 mutation in the NL population [16]. MSH2 mutations 
are associated with a higher risk of extracolonic cancers [17], especially endometrial [17], 
ovarian [18] and urological tumours [19,20,21], when compared with mutations in the 
other MMR genes. Those with a MLH1 mutation seem to present with less extracolonic 
cancers and an excess of CRCs, when compared with the MSH2 type [17,22]. Individuals 
with a MSH6 mutation appear to have a milder clinical phenotype with a later onset of 
CRC but an increased incidence of endometrial carcinoma [17,21,23]. Finally, the cancer 
risks in individuals with a PMS2 mutation remain largely unknown [24] but there does 
seem to be a later age onset of CRC in those families [19].  
 
Lynch syndrome accounts for approximately 1-3% of all cases of CRC worldwide [21]. 
In NL over 50% of incident CRC cases come from high- and intermediate-risk families, 
of which 2.7% have LS [25]. In addition to LS, an heterogenous group of families, 
labeled familial colorectal cancer type-X (FCCTX), fulfill the Amsterdam criteria but do 
not evidence microsatellite instability in tumors or have known MMR mutations [11]. 
Similar to what has been reported by others [13,26], FCCTX accounts for a high 
proportion of HNPCC in the NL population [10].  
 
Confirmation of LS means that all family members are encouraged to undergo predictive 
testing and/or follow recommended cancer screening. Regardless of carrier status, 
evidence suggests that the presence of hereditary cancer can have psychosocial, 
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emotional and behavioral impacts for all family members. Despite a growing number of 
studies, the full extent and specifics of these impacts are still unknown. A confirmed 
presence of hereditary cancer can bring much uncertainty to families as members face the 
realities of whether, when and where cancer will develop. When cancer does emerge, the 
indeterminacy of its treatment and outcome can have far-reaching emotional and 
psychosocial consequences for the entire family. Some studies have highlighted the strain 
hereditary disease can place on the family and its members [27,28]. 
 
To date, the focus of research efforts has been on the psychosocial implications of genetic 
testing with less emphasis on living with and managing cancer risk and/or cancer over the 
lifespan. The conclusion of meta-analyses and literature reviews is that genetic testing for 
hereditary cancer causes minimal psychological consequences [5,8,29,30]. Despite this, 
some quantitative evidence indicates that a subgroup of individuals experience difficulty 
in adjusting [1,31,32]. Further, qualitative findings suggest that certain individuals have 
difficulty adjusting in the short- and long-term following confirmation of genetic 
predisposition [27,33-36].  
 
An important contextual factor that seems to buffer the impact of hereditary cancer on 
family members is strong and open communication patterns [28,37]. Currently, 
researchers and theorists are placing more emphasis on exploring how variations in the 
family context may impact short- and long-term adjustment for those at risk for 
hereditary cancer [2,37-41]. Importantly, it is suggested that individuals with greater 
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social supports and who belong to families with open communication may have less 
psychosocial distress [28,42,43] and adjust better over the long-term [44]. 
 
Given its high cancer risks, LS has important behavioral implications. Evidence indicates 
that individuals can benefit from highly targeted screening and management strategies 
[45,46]. Colonoscopy screening, the only surveillance protocol in LS deemed to be 
effective [45], can reduce CRC-mortality by detection and removal of adenomas, the 
precursor of most CRCs [47]. In the NL population, colonoscopy screening prevented 
CRC and delayed the age of onset by more than 10 years for both male and female LS 
carriers [46]. Findings indicated an improvement in life expectancy of more than 15 years 
for females and four years for males [46]. Despite the documented benefits of 
colonoscopy screening in reducing CRC-mortality, morbidity related to the management 
of LS is a concern. Colonoscopic screening can result in serious adverse events such as 
perforation and bleeding [48,49] and less serious complications such as abdominal pain 
and bloating [48], all of which could be barriers to long-term, regular screening and/or 
surveillance.  
 
For female carriers of LS, the risk of developing endometrial cancer is high and can equal 
or exceed the risk of CRC [21]. Despite the lack of evidence-based data on the survival 
benefit of screening for endometrial and ovarian cancer, some recommend annual 
transvaginal ultrasound and endometrial biopsy starting at age 35-40 years [21]. Others 
propose this annual screening start earlier at 30-35 years of age [13,50]. The authors of 
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the NL study concluded that screening did not result in earlier detection of gynecological 
cancers [51]. What is proposed is a hysterectomy and oophorectomy once childbearing is 
complete, particularly after the age of 40 [21].  
 
LS also predisposes at-risk individuals to extracolonic cancers such as gastric, small 
bowel, urinary tract and pancreatic. A recent study concluded that 61% of cancer deaths 
in LS were related to non-CRC and non-endometrial cancers [52]. While some authors 
propose regular screening for mutation carriers with a family history of gastric, small 
bowel and/or urinary tract cancers [53], recently revised guidelines suggest that 
surveillance for these cancers should only be performed in a research setting as the 
benefits remain unknown [21]. However, some authors maintain that cancer screening be 
tailored to the extracolonic expression history of the specific LS mutation [24].  
 
Even though individuals with LS have to make important decisions about screening and 
disease management, only a limited number of studies have identified behavioral 
adjustment in the post-genetic testing phase as an important area for research inquiry 
[2,5,29,30,54,55]. In addition, most of this research is quantitative and more focused on 
screening adherence rates than barriers to and/or facilitators of timely access to 
recommended screening and follow through from diagnostic testing to treatment and 
ongoing surveillance. There is some qualitative evidence which suggests that the health 
care system itself can be a significant barrier to individual and family willingness and 
ability to follow recommended protocols for LS. Specific reference has been made to 
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challenges such as ineffective coordination, non-person centered care, limited provider 
knowledge and expertise, and inadequate provider/clinician communication skills, among 
others [36]. A recent review on colonoscopy screening in primarily average risk 
populations concluded that challenges with the bowel preparation, lack of knowledge 
about the importance of CRC screening and practical issues (e.g., transportation, costs, 
scheduling) are major barriers to participation [55]. The authors also suggested that a 
positive attitude towards screening, physician recommendation and having a family 
history of CRC facilitate screening [55]. 
 
What also remains unclear is how psychosocial, emotional and familial factors impact 
health-related behavior following confirmation of risk. There is some evidence to suggest 
that psychological distress may interfere with an individual’s ability to adhere to 
recommended disease management strategies [56,57]. Findings from a study of carriers 
of LS found that those who did not undergo a colonoscopy within six months following 
genetic test results were six times more likely to have depressive symptoms compared to 
those who did participate in screening [58]. These results suggest that cancer screening 
may facilitate adaptation to living with LS and may moderate emotional distress [58]. It 
is also conjectured that individuals living in supportive families with open 
communication are more likely to follow recommended protocols [59-62]. Clearly there 
is a need to further assess whether psychological and familial factors are impacting an 
individual’s ability to manage LS over time. 
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Perceptions of risk have been another area of research focus in relation to hereditary 
cancer. Some authors have suggested that awareness of familial cancer patterns, 
personal/family experiences with cancer and communication within the family influence 
risk perceptions. Risk perceptions could then in turn impact behavioral adjustment to the 
disease, particularly recommended screening and health promotion strategies [63,64]. A 
recent review on risk perceptions in high-risk populations concluded that psychosocial 
factors such as worry, distress and depression were consistently associated with 
perceptions of risk [65]. The authors also indicated that worry could influence screening 
behaviors [65]. 
 
Summary 
While there is an expanding research base on the psychosocial implications of genetic 
testing and a confirmed presence of hereditary cancer, less is known about psychosocial 
and behavioral adjustment in the long-term. Given the uncertainty of when and where 
cancer could develop and the necessity of adhering to screening protocols and/or cancer 
treatment and surveillance, adjustment may be influenced by multiple, interacting factors. 
Furthermore, the familial nature of LS can result in implications for the entire family. 
Currently, there is a paucity of research on the roles played by family dynamics, 
communication and support in influencing adjustment. While screening behavior 
adherence rates have been explored, little is known about whether they are maintained 
over time or how personal, health care provider and system factors facilitate or impede 
 
 
12 
 
adherence. Finally, there is a dearth of literature on whether psychosocial and emotional 
factors influence adherence to recommended disease management strategies. 
 
Program of Research 
The intent behind this section is to provide the reader with an insightful overview of the 
research program to date. The program of research, from which the doctoral work 
emerged, was comprised of several empirical studies. The studies were components of a 
multiphase program of research funded by the Canadian Health Services Research 
Foundation, the Canadian Institutes for Health Research (CIHR) through the Colorectal 
Cancer Interdisciplinary Health Research Team at the University of Toronto and 
Memorial University and the Atlantic Medical Genetics and Genome Initiative, funded 
by Genome Canada.  
 
As an initial step to facilitate a program of research on CRC, the Newfoundland Familial 
Colorectal Cancer Registry (NFCCR) was established in 1999 [10], which served as a 
major infrastructure component for all subsequent CRC research. The multiphase 
program of research across Newfoundland and Labrador and Ontario aimed to advance 
knowledge about the determinants, impact and control of familial colorectal cancer. 
Phase I (2000-2008) of the research entitled “Interdisciplinary Studies of the 
Determinants, Impact and Control of Colorectal Cancer: A Genetic-Epidemiological and 
Population-Based Approach” consisted of infrastructure development, research projects, 
capacity (training) building and knowledge translation. Phase II (2006-2011), entitled 
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“CIHR Team in Interdisciplinary Research on Colorectal Cancer”, was designed to 
build on Phase I findings and focused on the impact of genetic and non-genetic factors on 
CRC etiology, clinical outcomes, screening and psychosocial functioning. As part of the 
Phase II funding this researcher received a CIHR studentship (2006-2007) and, from 
September 2006 onward, was an active and contributing member of the interdisciplinary 
research team. 
 
As part of the larger interdisciplinary research team, team members took a leadership role 
in systematically examining the psychosocial, emotional and behavioral impact of 
participating in genetic testing for and living with hereditary cancer. The principle driver 
behind the current research agenda was to explore individuals and families experiences 
with a high cancer presence and confirmation of a hereditary link, and to highlight care 
needs, as well as potential/actual barriers to necessary health care services. The 
overarching objective was to use findings from both quantitative and qualitative studies 
to identify modifiable factors that could be potential targets of innovative strategies to 
improve disease prevention and management. The target outcome was to develop a 
framework to guide the delivery of clinical genetics services in the province’s four 
regional health authorities (RHAs). It was anticipated that such a framework would help 
clinicians involved in various aspects of the cancer care continuum to better determine 
individual and family needs and preferences and to use this information to deliver timely 
and appropriate care. 
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Phase I 
The team’s research in Phase I consisted of a quantitative and qualitative study. The first 
study under Phase I, “Psychosocial and Behavioral Impact of Predictive DNA Testing for 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC)” was conducted in 2004. Ethics 
approval for the full study and consent protocol were received in July 2003 (Appendix 
B). The primary objective of the quantitative study was to systematically investigate the 
psychosocial and behavioral impact associated with genetic counseling/testing for 
hereditary non-polyposis colorectal cancer, also known as LS. The study involved a 
quantitative survey, using standardized and researcher-developed scales, of 120 carriers 
and non-carriers of LS who were accrued from a population-based registry in NL.  
 
The target population was individuals from high risk families who were referred to the 
Provincial Medical Genetics Program of Newfoundland and Labrador (PMGP-NL). 
Eligible participants for the study were in families who had participated in predictive 
DNA testing and received confirmation of a MSH2 mutation on intron 5 and exon 8 [16]. 
With the exon 8 mutation identified more recently (early 2000’s) than the intron 5 
mutation (early 1990’s), there was a larger cohort available from the latter group for 
research purposes when data collection commenced in 2004.  Details on the sampling 
plan for this study are outlined in Appendix C. 
 
Preliminary analysis of the quantitative study results indicated that insufficient 
information was available on the psychosocial and behavioral impact of genetic testing 
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on individuals living in families with hereditary colorectal cancer. In summary, the 
findings provided the research team with limited insight into the role played by 
variant/similar family contexts and personal experiences in motivating individuals to 
become involved in genetic testing for LS, in shaping perceptions of the process and 
reactions to test results, and in facilitating or hindering adjustment to a being a carrier or 
non-carrier.  
 
The second study under Phase I was a two-stage qualitative study (2004-2007) designed 
to clarify and augment quantitative findings. Ethics approval for the study and consent 
protocol were received in April 2004 (Appendices D and E). The main objectives of the 
“Psychosocial and Behavioral Impact of Predictive DNA Testing for Hereditary Non-
Polyposis Colorectal Cancer (HNPCC)” were to explore individual and families’ 
experiences with cancer, reactions to and communications around being informed about 
the potential hereditary basis for the familial cancer, experiences with genetic testing, and 
psychosocial and behavioral outcomes in the short- and long-term following genetic 
testing. A second aim of the study was to determine the clinical services (genetic 
counseling, screening/surveillance, therapies and interventions) needed by individuals 
and families residing in each of the provinces’ four RHAs and highlight barriers to care. 
The long-term goal was to develop useful strategies for removing/modifying 
perceived/actual barriers to clinical genetic services and healthy living (illness 
prevention/health promotion behaviors).  
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This study used a grounded theory approach to data collection and analysis. In this 
instance, common perceptions shared by individuals in families with LS were explored. 
The inductive approach to studying phenomenon is focused on generating as opposed to 
testing theory and, as conceptualized by Glaser and Strauss (1967) [66], substantive 
theory is seen as emerging from a substantive area of inquiry. The strength of this 
approach is that the interest is not on merely describing how individuals experience a 
particular phenomenon but rather how information is received and assimilated into 
existing belief structures in a way that it becomes a stimulant for desired behavior. It was 
also conjectured that by using a grounded theory approach to data collection relevant 
theoretical constructs would be identified and developed in such a manner that 
quantitative measures could subsequently be generated to measure them. In grounded 
theory, theoretical sampling is an important tool for data collection and analysis. This 
form of sampling involves the deliberate selection of participants based on their 
experience with the area of interest and the needs of the emerging theory [67]. Details on 
the sampling plan for the qualitative study are provided in Appendix C. 
 
The majority of these participants were from families with the intron 5 splice site of the 
MSH2 gene and had participated in genetic testing eight to ten years prior to being 
interviewed. With the identification of an additional MSH2 mutation, exon 8 deletion, 
family members were now available to be interviewed closer to the time of genetic 
testing.  Stage two of the qualitative study involved using a modified grounded theory 
approach, designed for a Masters thesis, and was conducted with an additional seven 
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individuals from families with the exon 8 deletion [68]. The purpose of the study was to 
augment the conceptualizations of the constructs generated in stage one of the study. The 
findings supported the proposed constructs and indicated that living in a family with a 
strong history of cancer shaped personal beliefs, risk perceptions and emotional readiness 
for genetic testing. While acknowledging the helpful support received from genetics 
personnel, the real work of emotionally adjusting to the results of genetic testing occurred 
at the individual and family levels. Personal and family challenges in managing LS 
interfered with the psychosocial and emotional adjustment of both carriers and non-
carriers. Being open to and having family support emerged as being significant. 
Interactions with health care providers and the system also had implications for the 
psychosocial, emotional and behavioral adjustment of individuals and families. 
 
The substantive theory, “Confronting and Accepting the Challenges of Living in Families 
with Genetic-Linked Diseases” (see Figure 1.1), was generated from both qualitative data 
bases from interviews with carriers and non-carriers in LS families. The theory broadly 
conjectures that the situational and experiential contexts defining familial cancer are 
important forces influencing how well individuals accept the hereditary link to cancer, 
are motivated to become involved in genetic testing and adjust to their carrier or non-
carrier status in the short- and long-term. The psychosocial and behavioral processes 
captured by the theory suggest three major constructs: (a) living in families with a strong 
history of cancer, (b) becoming aware of genetic testing and living the process, and (c) 
struggling to adjust. 
 
 
18 
 
Figure 1.1: Confronting and Accepting the Challenges of Living in Families with 
Genetic-Linked Diseases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The first construct, living in families with a strong history of cancer, describes the phase 
prior to genetic testing for LS. It provides insight into the relevancy of the family context 
for shaping cancer risk perceptions and, ultimately, preparing family members for 
becoming involved in genetic testing. It depicts what it is like to live in families where 
there is an ominous presence of cancer and to eventually awaken to the idea that the 
cancers could be hereditary. 
 
The second major construct, becoming aware of genetic testing and living the process, 
provides insight into a complex process that individuals living in high risk families are 
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required to navigate to confirm their LS status and provide guideposts for future actions. 
It outlines how family members decide to become involved in genetic testing, react to 
being informed about their carrier status, perceive the supportiveness of genetics 
personnel, understand their risk and are willing to communicate genetic testing findings 
within and outside the family network. The degree of involvement in the genetic testing 
process is heavily influenced by how well individuals understand their risk for LS, accept 
the utility of genetic testing for confirming that risk, are willing to assume the psycho-
emotional repercussions in the short- and long-term, and feel supported by members of 
formal and informal networks. 
 
The third construct, struggling to adjust, focuses on the psychosocial, emotional and 
behavioral adjustment in LS families in the short- and long-term post-genetic testing. 
Adjustment is best defined as an evolving process that ebbs and flows in response to 
changing personal and family experiences in the management of long-term cancer risk 
and emergence of cancer in the self and/or others. Personal characteristics (e.g., attitudes, 
beliefs, practical knowing based on prior experiences, openness to knowing the 
implications of LS) and the family environment (e.g., supportiveness, availability of 
resources, dynamics, communication patterns) interact to influence psychosocial and 
emotional adjustment. Psychosocial and behavioral adjustments also waver in response to 
evolving experiences and critical events (e.g., personal and family challenges, 
progression to affected states, the suffering and early deaths of affected relatives). 
Finally, adjustment is influenced by interactions with health care providers/system, 
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particularly in relation to screening/treatment, and ease of access to a supportive health 
care system (meaningful information, timely screening/treatment, psychosocial supports). 
These experiences can act as barriers to or facilitators of adjustments. The construct 
focuses on the personal and family challenges of managing LS over time, the importance 
of openness and support within the family, dealing with recommended 
screening/treatment and health care providers/system, and managing risks for younger 
family members. 
 
The first two constructs, living in families with a strong history of hereditary cancer and 
becoming aware of genetic testing and living the process, are conjectured to exert a direct 
impact on each other and a direct and indirect impact on struggling to adjust. It is also 
proposed that accepting the challenge is the unifying thread that links the constructs, 
signifying that a change in one area has repercussions for other areas. Finally, all three 
constructs are believed to exert a direct impact on quality outcome, which is seen as an 
evolving state. The third construct, struggling to adjust, is also conjectured to mediate the 
effects of living in a family with a strong history of cancer and becoming aware of 
genetic testing and living the process on quality outcome.  
 
Phase II 
In Phase II of the program of research a proposal for psychometric testing was 
successfully submitted to CIHR for funding as part of the larger research project “CIHR 
Team in Interdisciplinary Research on Colorectal Cancer” (CIHR # - FRN-79845) 
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(2006-2011). The sub-project, “Psychometric Testing of Scales for Monitoring the 
Psychosocial and Behavioral Impact of Genetic Testing for Hereditary Non-Polyposis 
Colorectal Cancer” (2008-present), was designed to build on the previous quantitative 
and qualitative studies. Ethics approval for the study and consent protocol were received 
in February 2008 (Appendices F and G). The target population for this study was 
individuals at 50% risk for inheriting LS who had participated in predictive DNA testing 
and were informed of their carrier status. The participants were recruited from 
population-based probands comprising the PMGP-NL.  
 
Immediately prior to the study, 272 carriers and 295 non-carriers had been confirmed 
from the PMGP-NL and entered into a Cancer Screening Data Base. This data base was 
developed for a component of the larger study which retrospectively profiled the actual 
screening practices of carriers and non-carriers following genetic testing. The rationale 
for using this data base was that actual screening practices will be, ultimately, linked to 
the psychosocial and behavioral self-report data obtained over time following 
confirmation of the psychometric properties of the monitoring tools.  
 
At the time of the study, the information available on registrants comprising the Cancer 
Screening Data Base was reviewed to identify potential participants. Registrants excluded 
from consideration included those who did not have a confirmed carrier status (i.e., 
obligate carriers, presumed positive, or inconclusive results with unknown risk), had not 
participated in genetic testing, had died since their name was entered into the data base, 
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had no contact information, or had refused to be contacted for research purposes. Details 
on the sampling plan for this study are provided in Appendix H. 
 
Relying on the qualitative study data, the research team used the operational indicators 
comprising the descriptors of each property defining each category of the substantive 
theory to draft several scales. The first two constructs, living in families with a strong 
history of hereditary cancer and becoming aware of genetic testing and living the 
process, of the model were used to develop the Hereditary Diseases and Genetic Testing 
(HD-GT) scale which is capable of assessing experiences prior to, during and 
immediately following genetic testing. Comprising the research for a Masters thesis [69], 
the HD-GT was piloted tested in 75 carriers and non-carriers of LS (Appendix H).  
 
Psychometric testing of the HD-GT scale was based on the work of Ware and Gandek 
(1998) [70]. Preliminary findings indicated good data quality and potential usability of 
the scale under variant administrative conditions. All of the HD-GT subscales met the 
criteria for Likert scaling assumptions (i.e., approximate equivalence of means and 
variances, use of all response choices in the rating scale, amount of missing data, 
approximate symmetry in response distribution, linearity, item-convergent validity and 
item-discriminant validity) and evidenced very good reliability and validity. The various 
subscales of the HD-GT augmented what has been reported in the literature and provided 
new insights into the psychosocial impact of genetic testing for individuals and families 
with LS. Study findings suggested that a family history of cancer does have a significant 
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impact on decision-making regarding genetic testing. There were also indications that 
study respondents placed high value on having all potentially at-risk family members 
participate in genetic testing, but were often challenged trying to convince them to accept 
the need for testing. 
 
With regard to the genetic testing process, results indicated that most respondents placed 
high value on being emotionally prepared for genetic testing and having appropriate 
information, but not everyone required health care provider or family/friends support. As 
well, despite experiencing some emotional difficulty while waiting for test results, not 
everyone required support prior to and during the receipt of results. Finally, most family 
members wanted information about LS, and were perceived to understand it, but 
encountered some difficulties in communicating the information to other family 
members. In summary, study findings indicated that the subscales appeared to be 
sensitive enough to measure the wide-range of psychosocial implications of genetic 
testing. 
 
Analysis of the third construct of the model, struggling to adjust, revealed two dominant 
themes – one focusing on psychosocial and emotional adjustment and the other on 
behavioral adjustment in LS families. The Hereditary Diseases-Psychosocial and 
Behavioral Adjustment (HD-PBA) scale was developed to measure psychosocial and 
behavioral adjustment and is divided into two scales. The psychosocial adjustment data 
matrix provided the content for item generation for the Psychosocial Adjustment to 
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Hereditary Diseases (PAHD) scale, designed to assess the personal and family burden of 
LS and the perceived role of family in buffering its impact. The behavioral adjustment 
data provided the content for the Behavioral Adjustment to Hereditary Diseases (BAHD) 
scale. This scale, which is currently being tested, is designed to assess the experiences 
with screening/treatment, perceptions of health care quality, management of children who 
are at risk and what is needed to promote effective disease management post-genetic 
testing. 
 
Following pilot testing of all three scales in 2008, ongoing recruitment and data 
collection continued between July 2008 and July 2010. The HD-GT, PAHD and BAHD 
scales were administered to an additional 168 participants giving a final sample size of 
243 (140 carriers and 103 non-carriers of LS) (Appendix H). Preliminary testing indicates 
that the HD-GT and PAHD are psychometrically sound, reliable and valid scales. 
 
Program of Research for Dissertation 
This section is intended to provide the reader with details on this researcher’s personal 
contribution to the program of research and a clear distinction between individual and 
team effort. Upon joining the research team in 2006, this researcher was directly involved 
in: (a) analysis of the 2004 survey data for NL participants, (b) secondary analysis of the 
first two constructs of the substantive theory to collapse categories and generate items for 
the HD-GT, (c) development of a proposal for ethics review, and (d) pilot testing of the 
HD-GT and data analysis. As part of the CIHR studentship (2006-2007) and onward, this 
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researcher assumed the lead role for: (a) secondary analysis of the struggling to adjust 
construct of the qualitative data base, (b) using this data to develop two multidimensional 
instruments capable of assessing long-term psychosocial, emotional and behavioral 
adjustment to the presence of LS, and (c) the recruitment of additional participants, data 
collection and analysis for the psychometric testing of scales following the pilot study. 
 
Rationale for Dissertation Research 
In families with a confirmed LS presence, individual members have to deal with a 
complex disease which has multi-organ targets, variant familial trends with first cancer 
sites, highly variable potential onset times over the lifespan, and uncertain effectiveness 
of recommended screening/surveillance and treatment protocols. These evolving and, at 
times, challenging realities require individuals to adjust psychosocially, emotionally and 
behaviorally. Given the far-reaching psychosocial and emotional impacts for the entire 
family and behavioral implications for carriers, it is imperative that health care providers 
be able to assess short- and long-term adjustment to hereditary disease. 
 
Living with and managing lifelong cancer risk requires adjustment on many levels to 
achieve quality outcomes. Therefore, clinical monitoring tools that can evaluate 
adjustment are needed. These tools must be able to: (a) determine the presence and 
pervasiveness of personal/family burden in the short- and long-term, (b) identify a 
supportive milieu and communication openness in families, (c) identify barriers to and 
facilitators of screening/surveillance, and (d) assess the interaction of psychological and 
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behavioral factors in determining outcomes (e.g., health-related quality of life, 
morbidity/co-morbidity, mortality). 
 
Importantly, the clinical practice implications of this program of research are significant. 
Effectively managing LS with targeted, individualized screening and/or surveillance 
protocols are critical to quality health outcomes in this population. The provision of 
genetics services in primary health care must include support and resources for the entire 
family that go well beyond the immediate post-genetic testing period. A growing 
evidence base indicates that monitoring the short- and long-term adjustment of 
individuals is necessary in identifying those who may be experiencing challenges. 
Providing individuals with genetic testing results and information about recommended 
management protocols may be insufficient. Some individuals and families will need 
ongoing supports in dealing with psychosocial and emotional issues and assistance in 
accessing, coordinating and managing recommended screening/treatment.  
 
Finally, the clinical monitoring tools developed will need to be incorporated in cancer 
genetics services at various points before, during and following genetic testing. This will 
allow the researcher to assess the clinical utility of the tools in identifying and assessing 
those at risk for poor psychological and behavioral outcomes. It is anticipated that the 
data gleaned from the monitoring tools can be used to inform health care interventions for 
individuals and families facing the confirmed presence of a hereditary disease. 
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Research Objectives  
The specific research objectives guiding the dissertation work were as follows: 
1.  To explore the long-term psychosocial and emotional impacts of living in a 
family with a hereditary disease. 
2. To explore the role of the family context in facilitating/impeding psychosocial 
and behavioral adjustment to LS. 
3. To identify the facilitators of and barriers to screening and disease management in 
those with a confirmed mutation for LS. 
4. To determine how facilitators of and barriers to screening can be augmented or 
addressed. 
5. To develop items for the PAHD and assess its psychometric properties.  
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Background: Lynch syndrome (LS) is an inherited cancer syndrome with high risks of 
colorectal and extracolonic cancers. With its familial nature and uncertain clinical 
trajectory, LS has significant implications for individuals as well as all family members. 
The objective of this paper is to examine the long-term psychosocial and emotional 
adjustment to LS for carriers and non-carriers. 
Methods: A grounded theory study was part of a multiphase project examining the 
psychosocial and behavioral impact of predictive genetic testing for LS. Individual and 
small group interviews were conducted with 39 unaffected carriers, affected carriers and 
non-carriers from 15 families with the intron 5 splice site mutation or exon 8 deletion. 
Results: The study highlights the long-term personal and family strengths/challenges for 
both carriers and non-carriers who have been living in families with hereditary cancer 
many years beyond the initial genetic testing event. The findings indicate that carriers and 
non-carriers in LS families have variant experiences that are influenced by diverse 
personal and familial factors that can act as facilitators of and barriers to adjustment.  
Conclusions: Being at risk for LS is a condition that affects the individual and family 
with both requiring support over time. Genetic testing is one event along a continuum of 
lifelong disease management. The supportive and informative roles of genetic counselors 
and other health care providers, knowledgeable about managing LS, will be critical in 
promoting successful psychosocial adjustment and a reasonable quality of life. 
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Background 
Hereditary non-polyposis colorectal cancer, also known as Lynch syndrome (LS), is an 
inherited cancer syndrome with significant risks of colorectal (CRC) and related cancers 
for carriers of the gene mutation. With an unpredictable clinical trajectory and the 
importance of engaging in lifelong preventive health behaviors, LS has the potential to 
impact the psychosocial, emotional and behavioral adjustment of entire families affected 
by this condition. The focus of this paper will be on the long-term psychosocial and 
emotional adjustment to LS for carriers and non-carriers. 
 
Adjustment to the presence of hereditary cancer is defined as an evolving process that 
ebbs and flows in response to changing personal and family experiences in the long-term 
management of cancer risk and emergence of cancer in the self and/or others [1]. To 
understand adjustment in the short- and long-term it is necessary to examine a number of 
interactive factors defining it. Personal characteristics (e.g., attitudes, beliefs, practical 
knowing based on prior experiences, openness to knowing the implications of LS) and 
the family environment (e.g., supportiveness, availability of resources, dynamics, 
communication patterns) interact to influence psychosocial and emotional adjustment. 
Experiences with health care providers and the system can also interact with individual 
and family-based factors to influence behavioral adjustment to LS [2].  
 
Confirmation of hereditary cancer can bring lifelong uncertainty to all family members 
[3,4]. Carriers are faced with a syndrome characterized by an 85-90% penetrance rate [5] 
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in the development of variant and, often multiple, colorectal and extracolonic cancers. 
Lifetime risk estimates for a cohort of families within Newfoundland and Labrador (NL) 
have been determined to hover around 98.2% and 92.8% for male and female carriers, 
respectively [6]. LS accounts for approximately 1-3% of CRC cases worldwide [7,8]. In 
NL over 50% of incident CRC cases come from high- and intermediate-risk families, of 
which 2.7% have LS [9]. 
 
Clustering of certain cancers in families [10], in addition to early age onset, compounds 
the complexity and uncertainty of the disease. For some individuals, the reality of living 
with LS over time can involve a multitude of experiences that deviate far from expected 
norms. Despite evidence suggesting that hereditary cancer risk can be burdensome, 
existing data provides limited insight into how psychosocial and emotional adjustment is 
influenced by the complex interplay of individual, familial and health care factors.  
 
Furthermore, there is limited evidence on how psychosocial and emotional factors impact 
surveillance behaviors which are critical to effective disease management and reduced 
morbidity and mortality. While the benefits of colonoscopy screening have been 
demonstrated in the NL population [11] and others [12,13], there is a paucity of literature 
on the role played by psychosocial factors in facilitating or impeding adherence to 
recommended screening. The findings of one study examining the association between 
psychosocial outcomes and screening one month following receipt of genetic testing 
results suggest that those who fear dying soon tend to delay colonoscopy beyond the 
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recommended interval [14]. Qualitative evidence indicates that some individuals who feel 
burdened and overwhelmed in managing LS may take “time out” periods from 
recommended screening regimes [2]. 
 
One identified gap in research on hereditary cancer is the presence of useful and reliable 
information on long-term outcomes [3,15,16]. Several authors have emphasized the need 
to better understand the psychosocial, emotional and behavioral implications of harboring 
a genetic predisposition [14,17-19]. Quantitative studies focusing on short-term 
psychological outcomes post-genetic testing suggest minimal psychological impact [19-
23]. Most of these studies used standardized instruments for data collection which have 
been criticized for their limited sensitivity in detecting psychological distress in at-risk, 
non-clinical populations [21,24] or fully exploring the diverse experiences influencing 
individual responses to hereditary cancer [25]. As well, most quantitative studies, to date, 
have been limited to short-term follow up of individuals (i.e., 1-12 months) without 
consideration of the familial context or long-term adjustment [26].  
 
A recent review on the psychosocial impact of genetic testing for LS concluded that 
testing does not cause long-term distress in carriers unaffected with cancer but suggest 
that little is known about the impact on those who have developed cancer [27]. Given the 
earlier age of onset and emergence of variant cancers in LS, it is critical to conduct 
longitudinal studies so that experiences of those who develop cancer can be captured. To 
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fully understand the implications of living in families with LS, it is important to explore 
the lifelong experiences of carriers, affected and unaffected with cancer, and non-carriers. 
 
Although it may be difficult to draw conclusions about the long-term psychosocial and 
emotional impact of hereditary cancer [3,16,20,28], there are indications that a small, but 
significant group of individuals experience adjustment difficulties and perhaps distress 
[27-30]. Some individuals may have difficulty adjusting to living with hereditary cancer 
in the short- and long-term [2,3,31-34]. 
 
A research area that has received limited attention is the role of the family environment in 
influencing adjustment to genetic-based diseases. There is evidence that the family 
context may impact individual well-being, risk perceptions and health behaviors [35], in 
that individuals with greater social supports and who belong to families with open 
communication may be less prone to experience psychosocial distress [30,36,37] and 
adjust better over the long-term [16]. As well, it has been suggested that older family 
members can support younger family members [38,39] and encourage them to follow 
recommended cancer screening [38], and women may assume the role of coordinator and 
support [32], particularly when communicating important information about genetic 
counseling and testing [40].  
 
What these findings suggest is that reliance on individual-focused approaches to genetic 
counseling, without considering the family context, may be ineffective for long-term 
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management of genetic conditions, like hereditary cancer [3,26,36,41]. Personal and 
family resources have been shown to impact the psychosocial and emotional well-being 
of all members in the short- and long-term [4,23,24,28,35,42-44]. From a clinical 
perspective, it is imperative that we develop greater insight into how the family context 
impacts adjustment and use this information to develop a family-based approach to health 
care for individuals with genetic-based diseases [36,41]. 
  
The Present Study 
The goal of the present study was to examine the long-term psychosocial and emotional 
adjustment to LS among carriers and non-carriers. This study is unique because, to date, 
there is limited data available on both carriers and non-carriers who have been living with 
cancer risk within the self and/or others for many years beyond the initial genetic testing 
event. To our knowledge, this is the first study to provide adjustment data for carriers, 
affected or unaffected with cancer, and non-carriers for several years following 
confirmation of hereditary cancer (Table 2.1). The study highlights the long-term 
personal and family challenges for both carriers and non-carriers living in families with 
hereditary cancer, as well as the facilitators of and barriers to adjustment. 
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Table 2.1 Participant characteristics (N = 39)  
 
ID 
 
Family 
 
  Gender  Post-GT a  Age b  Carrier Onset Age Cancer Types c 
23 
24 
25 
26 
31 
8 
22 
30 
2 
7 
9 
32 
20 
21 
6 
15 
16 
10 
27 
28 
29 
11 
12 
13 
14 
18 
1 
3 
4 
19 
5 
37 
38 
39 
33 
34 
35 
36 
17 
1B 
1B 
1B 
1B 
1B 
1C 
1C 
1C 
2A 
2A 
2A 
2A 
2B 
2C 
2D 
2E 
2E 
3A 
3A 
3A 
3A 
3B 
3B 
4 
4 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
Female 
Female 
Male 
Female 
Male 
Male 
Male 
Male 
Male 
Male 
Female 
Female 
Female 
Male 
Female 
Female 
Female 
Female 
Female 
Male 
Female 
Male 
Female 
Female 
Male 
Male 
Female 
Female 
Female 
Female 
Female 
Female 
Male 
Male 
Male 
Female 
Female 
Female 
Female 
6.42 
6.42 
8.50 
2.42 
7.50 
3.67 
6.50 
7.42 
7.83 
8.33 
8.08 
9.58 
9.08 
9.08 
6.92 
2.75 
2.75 
7.00 
8.17 
8.17 
7.50 
8.42 
7.42 
8.42 
6.42 
7.42 
0.75 
0.92 
0.75 
0.08 
2.33 
3.17 
3.08 
3.25 
2.25 
2.83 
3.75 
3.75 
2.75 
57 
78 
52 
32 
47 
28 
26 
57 
38 
37 
41 
69 
50 
50 
53 
78 
79 
42 
51 
43 
33 
76 
55 
59 
45 
42 
43 
50 
48 
63 
52 
50 
46 
55 
66 
43 
44 
42 
75 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
Yes 
Yes 
Yes 
Yes 
No 
No 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
No 
No 
No 
No 
Yes 
Yes 
No 
Yes 
Yes 
No 
No 
Yes 
No 
Yes 
No 
--- 
46 
42 
--- 
45 
--- 
--- 
--- 
--- 
--- 
39 
35 
33 
--- 
--- 
72 
74 
--- 
43 
45 
--- 
39 
26 
--- 
--- 
--- 
--- 
--- 
49 
54 
--- 
46 
--- 
--- 
--- 
40 
--- 
--- 
--- 
--- 
CRC/EC 
CRC/GA 
--- 
CRCx2 
--- 
--- 
--- 
--- 
--- 
CRCx2 
CRCx2/EC/GA/SK 
EC/BR/VA 
--- 
--- 
CRC 
CRC 
--- 
Ovarian 
CRC/DUO 
--- 
CRCx2/SK/KD  
CX 
--- 
--- 
--- 
--- 
--- 
CRC 
SK 
--- 
KD/EC 
--- 
--- 
--- 
EC 
--- 
--- 
--- 
Note. Families 1B to 3B, 4, 5 and 9 have the intron 5 mutation and families 6 to 8 have the exon 8 
deletion. The use of A, B, C, D or E after the family number denotes separate nuclear families 
within a particular extended family.     
 
a Years since genetic testing. 
b Age at first interview. 
c CRC=colorectal; CX=cervix; EC=endometrial; GA=gastric; SK=skin; BR=breast; VA=vaginal; 
KD=kidney; DUO=duodenal. 
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Methods 
Study Design 
A grounded theory study [2] was part of a multiphase project examining the psychosocial 
and behavioral impact of predictive genetic testing for LS. The Health Research Ethics 
Board, Memorial University, approved the study protocol. The rationale for using 
grounded theory is presented in Watkins et al. (2011) [2]. 
 
 
Participants 
Details on the target population and predictive genetic testing have been reported 
elsewhere [2]. A purposive sample of 39 individuals from 15 families who had 
participated in genetic testing and knew their status was selected from the accessible 
population. This article focuses on the 23 carriers and 16 non-carriers (Table 2.1) from 12 
families with the intron 5 splice site mutation and three families with the exon 8 
mutation. The mean time from genetic testing to initial interview was 5.4 (±2.6) years 
(range .1 to 9.6) and age at the first interview was 51.2 (±13.8) (range 26 to 79). 
 
Procedure 
Following initial contact and informed written consent, two interviewers conducted 60 to 
90 minute interviews with participants either individually or in small groups. Information 
on the procedure, interview questions and data analysis are presented in a previous 
publication [2]. Data analysis revealed a substantive theory, “Confronting and Accepting 
the Challenges of Living in Families with Genetic-Linked Diseases” which is comprised 
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of three major constructs (living in families with a strong history of cancer, becoming 
aware of genetic testing and living the process, and struggling to adjust) which exert 
separate and interactive effects on each other. The data presented in this article are 
restricted to examining the construct, struggling to adjust, specifically the psychosocial 
and emotional impact of hereditary cancer for individuals and families.  
 
Results 
Living in families with hereditary cancer may have psychosocial and emotional 
implications for all family members. The implications go well beyond individual genetic 
test results to the family environment where many interactive factors influence how 
carriers and non-carriers manage a genetic-based disease. The interactive effects of 
genetic and environmental factors can facilitate or impede psychosocial and emotional 
adjustment to living with familial cancer.  
 
Similarities and discrepancies were observed in how study participants and their families 
responded to the presence of LS. The findings revealed a family meaning context, with 
members having shared similar/differing experiences and/or reactions to the confirmation 
of a genetic link to cancer. Although most individuals and families deal with the ominous 
presence of hereditary cancer in a positive manner, the potential exists for significant 
personal and family burden. 
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Adjusting to Lynch Syndrome – Personal and Family Implications 
Wide variations were observed in how the study sample perceived personal and family 
impacts of LS. While most acknowledged the importance of knowing about their cancer 
risk, some were burdened by this reality. Periods of intense exposure to familial cancer 
seemed to provide participants with an extensive practical knowing that appeared to be 
both informative and burdensome. Some individuals and families were empowered to 
effectively manage the condition, whereas others were challenged to do so and struggled 
to grasp an understanding of its implications personally and for significant others. 
 
Personal Strengths/Challenges 
Confirmation of LS in a family involves adjusting to an unfolding, complex disease state 
as individuals struggle to come to terms with the uncertainty of who will get cancer, the 
timing/location of cancer episodes and disease outcomes. Dealing with the threat of 
cancer or its development, caring for others with cancer, adhering to recommended 
screening, enduring cancer treatment and contemplating children’s risk are potential 
sources of psychosocial and emotional burden. The current study findings suggest that, 
on a personal level, the challenge is to embrace a positive attitude and not dwell on the 
uncertainties of hereditary cancer. Most family members recognize the importance of 
maintaining a positive outlook and accepting the unknowns: “We don’t dwell on it [LS] 
and we don’t let it get to us. It is one of those things where we know it’s there and we’re 
just going to accept it.” [I23, Fam1B] 
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A sense of inner personal strength and resilience were evident in the narratives of many 
carriers. This observation held for both those affected and unaffected with cancer. The 
findings suggest that most accepted the realities of LS and endeavored to think positively 
and face each day without focusing on the uncertainties. One male participant, who had 
not developed cancer, had this to say: “I don’t dwell on anything since I had this [LS]. I 
don’t even think about it. No, I live a day at a time. I live a good happy life. I am not 
interested in negative things.” [I30, Fam1C]. Another participant, who had experienced 
cancer twice, made a similar comment: “We just got to carry on and be strong.” [I11, 
Fam3B] 
 
Another male carrier, who was also unaffected, firmly believed that attitude plays a 
significant role in shaping health outcomes. For him, psychosocial and emotional factors 
can affect disease onset even when there is a genetic predisposition for it.  
 
I think people’s attitude really has an effect upon outcomes as well. I think stress 
plays a part in the illness. …Who’s to say that my attitude has probably helped 
keep me from developing something? When I do become ill, if I’m able to 
maintain the attitude that I have now, I think I would have a better chance of 
survival. [I21, Fam2C] 
 
Some carriers, who were unaffected with cancer, had reached critical milestones in that 
they had surpassed the age at which most of their family members had developed and/or 
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succumbed to cancer. This reality could potentially evoke anxiety and fear but also 
reassurance that one had “beat the odds”. One of male carriers had this to say: “I’ve 
heard of some families of my cousins, the entire generation in their 40’s were wiped out 
so obviously that must be very frightening if you’re 30. …my father was in his 20’s you 
know, I’m 50.” [I21, Fam2C] 
 
Many carriers struggle to reconcile the gap between the cognitive awareness of risk status 
and emotional acceptance while waiting for the disease to manifest. Being aware of and 
caring for others who develop cancer are stark reminders of things to come. The 
narratives of unaffected carriers contained evidence of personal struggles, especially 
during reflective periods. 
 
Will I ever be faced with cancer? If I do, then how will I feel? I always look back 
when I’m talking to her [mother]. What if this was me? Would I feel any different 
by what someone is saying to me? …I struggle with that. I can’t relate to that 
because I couldn’t say what I would or wouldn’t do in that situation. [I36, Fam8] 
 
The reality of LS is that it does not occur in isolation. The narratives of some carriers are 
reflective of how the burden of managing LS can be compounded by stressful life events 
and other illnesses. Despite being cancer free, one female carrier had to deal with the 
interactive and cumulative effects of dealing with LS, cancer screening for over 20 years, 
heart disease and diabetes, among others. Due to previous abdominal surgery, 
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recommended colonoscopies have become more difficult for physicians to perform and 
for her to endure. Her words capture the toll on her physical and emotional well-being 
and her challenge to maintain a positive outlook.  
 
Looking at me now, you wouldn’t say I had a care in the world. And some days if 
you could see me, you’d swear I had one foot in the grave. …And there’s days 
like yesterday I kept saying, ‘Lord I don’t know if I can do this. I don’t know if I 
can make it through another day and try to act as if everything is okay. It’s hard to 
wear a smile when you feel like you’re falling apart at the seams.’ [I10, Fam3A]  
 
The intensity of reactions to being affected with cancer seems to be influenced by the 
number of personal bouts and exposure to cancer in immediate family members. For 
most, there is the realization that when cancer surfaces initially and is treated 
successfully, this is only the beginning of a lifelong journey filled with uncertainty about 
future health states. One woman who followed recommended screening based on her 
family history had two primary early stage cancers. Even though she tried not to dwell on 
her situation, her words reflect concern for her future well-being: “I don’t sit and dwell. 
Yes, we all do; especially last year when I sort of got down and got cancer again. …What 
else is going to happen to me now? Oh God, when is it going to break out next?” [I37, 
Fam7] 
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A similar story was related by a male participant. His recent experience with cancer, 
signs and symptoms of health changes, and cancer onset and death among younger family 
members fueled heightened distress and anxiety propelling him to take action.    
 
But after I had my operation [colon cancer] I phoned up for another appointment 
[for diagnostic testing] and they told me that it could be another 6 months before I 
get in and my year was up then right. …So I phoned the doctor that operated on 
me and I got in within 2 weeks. I couldn’t wait another 6 months. I was 
frightened. [I31, Fam1B] 
 
Long-term cancer survivors seem to have developed a sense of resilience characterized 
by a positive attitude and increased emotional strength. One woman who had survived for 
35 years and endured four previous primary cancers spoke about her fifth bout. Despite 
significant long-standing challenges with cancer and its complications, her words capture 
an approach to living that has enhanced her emotional, social and physical well-being. 
 
Now that episode with stomach cancer was 15 years ago and I was living alone. 
So then I had the ileostomy but that didn’t bother me psychologically because it 
was such a relief after spending so much time in the washroom. I recovered from 
that. I was fine. I was getting a new lease on life. I was 54. Apart from having 
cancer I am a real physical fitness sort of person. ...I am a survivor because during 
these years I got a black belt in karate and that has helped me. [I32, Fam2A] 
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Similar to carriers, the stories of non-carriers reflect the need to stay positive in order to 
face the challenges of LS. One non-carrier echoed the sentiments of others when he 
suggested that a positive attitude is important to the person facing cancer: “You got to 
have a good outlook or you are not lasting. I think that it [positive attitude] has a lot to do 
with it [survival].” [I33, Fam8]  
 
Some non-carriers are challenged by having to give up regular screening for cancer. 
While most experience relief, others find it difficult to discontinue recommended 
screening for LS. It seems that screening, particularly for those who did it for years prior 
to genetic testing, provided a safety net and reassurance that all is well. One participant 
spoke about how her loss has not dampened the need to be vigilant. “Now that the crutch 
is gone, I just watch myself a little bit more carefully. If there is any change in my bowel 
habits, then I think, I suppose it’s been a little while since I had that colonoscopy done.” 
[I3, Fam6] 
 
In contrast, other non-carriers, who had screened for years prior to genetic testing, 
concluded that further action could be taken to reduce a person’s overall risk of cancer. 
Following receipt of negative genetic testing results one participant realized that he 
should be taking better care of his health: “Alright, I’ll pay a little bit more attention to 
what I’m doing with myself. At that point maybe I did lead a more healthy lifestyle.” [I2, 
Fam2A] 
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Family Burden  
Hereditary cancer is a family matter that can create psychosocial and emotional 
challenges for all members. Striving to be positive and enduring one’s lot are not easily 
achievable for everyone, particularly when considering the broader implications of LS. 
Living with the uncertainty of cancer, losing younger family members at an early age and 
dealing with the challenges of regular screening can be overwhelming and emotionally 
taxing. The only certainty is that any family member at risk can be diagnosed with cancer 
at any point in time: “Nobody likes the idea of worrying and wondering if this test is 
going to show that I got something wrong this time.” [I10, Fam3A]  Depending on the 
person’s inner strength and resilience, too much worry and concern has the potential to 
evolve into an emotional barrier impeding effective disease management. Study findings 
highlight the fact that hereditary cancer is a family-focused disease which can evoke 
burden in close and extended members regardless of one’s carrier status. 
 
A source of burden for carriers is non-accepting children. One female carrier expressed 
concern for her children and wondered if exposure to her struggles will prevent them 
from accepting and managing their cancer risk: “I don’t think they want to know [carrier 
status] because they’ve seen me go through it – the screening, prep, and prognosis 
because I have had two cancers. I think that’s what’s going to hold my children back.”  
[I20, Fam2B] 
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Other carriers spoke about the impact of LS on young family members. With cancer-
related deaths occurring at younger and younger ages, parents are worried about what the 
future might hold for their children. One woman’s words capture the sentiments 
expressed by many: “When I think of the cousins who are gone and the families they 
have left. The young men … every time we get together for family gatherings especially 
Christmas and you see all those young family members and you wonder what becomes of 
them.” [I19, Fam6] 
 
Carriers also found it challenging to deal with children who have experienced the 
suffering and death of young family members. The following text exemplified the 
significant burden that hereditary cancer can bring to a family: “They [children] just lost 
their cousin, 17 years old. How do they deal with that? We’re finding it difficult to deal 
with and, not only that, we watched her die.” [I38, Fam7]  
 
While not at risk personally, non-carriers in LS families are an integral part of the social 
and familial contexts and often have to endure the emotional implications of caring for 
others at-risk or with cancer and dealing with the loss of significant others. Thinking 
about who would be affected next is emotionally draining as individuals struggle to 
adjust to a constantly evolving condition: “It is very upsetting. When I find out that they 
[relatives] have cancer, it really makes me think, ‘Who’s going to be next?’ That fear is 
always there.” [I13, Fam4]  
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Non-carriers struggle to remain optimistic and not dwell on what is happening around 
them. However, this can prove to be very difficult as more and more family members 
develop cancer. One woman who tested negative for LS had this to say: 
 
Since I’ve had this wonderful news that I don’t have the mutation, two of my 
younger cousins are now having problems. …So like you go along in this family 
and you’re thinking. …It’s not just off there in the distance. It’s right up there in 
your face all the time. [I3, Fam6]  
 
Summary 
While most participants strived to maintain a positive outlook in dealing with LS, 
confirmation of this syndrome had personal and family psychosocial and emotional 
implications. As conveyed by the words of study participants, it is sometimes a struggle 
to maintain a positive outlook when dealing with a disease that has an uncertain 
trajectory, time of onset and outcome for the self and others. While a small number are 
able to face the disease with incredible strength and resilience, the majority of carriers 
and non-carriers are burdened. Although the presence of LS is manageable for most, 
there is a subgroup that struggle with it. While carriers have to confront challenges that 
go beyond worrying about personal cancer risk, the findings also suggest that non-
carriers have to endure the emotional consequences of living in LS families. 
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Family Connectedness  
Family connectedness plays a crucial role in helping individuals deal with the adversities 
of living with hereditary cancer. As defined by study participants, family connectedness 
involves having a supportive environment, access to resources and open communications 
to help manage the many challenges posed by LS. Any one member’s ability to adjust to 
being a carrier or non-carrier is shaped, in part, by what is happening in the family. 
Strength in numbers is a function of close ties between and among extended family 
members.  
 
When family relations have always been characterized by a special closeness and open 
communication, there is no change following confirmation of LS. In such instances, 
individuals maintain ongoing contact for the purpose of keeping everyone current on 
what is happening to family members, facilitating openness and providing support: “As 
soon as one finds out something else about the other – look out the phone don’t stop 
ringing. Because if you tell one it’s like the pony express, everybody knows it … That’s 
part of getting us through it [LS].” [I27, Fam3A] 
 
All of the carriers referenced the comfort derived from having at least one person who 
knows and understands what it means to live with hereditary cancer. The commonality of 
interests, risks and concerns often means more frequent contact and open discussions. It 
seems that when a supportive milieu is present, carriers are helped to become more open 
to and accepting of their high cancer risk. From the perspective of one young man, the 
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presence of LS has helped facilitate greater sharing of experiences: “In some sense it has 
created a kind of unique bond in our family – you got something in common with some 
of your cousins’ and uncles’. Things that you’re going through together … You can … 
talk about things.” [I8, Fam1C]  
 
A parent with several children with the LS mutation also observed that more open 
communication and greater access to supportive others not only buffers the impact of LS 
syndrome but also encourages more effective disease management. 
 
The only thing I find now, the children who are positive, they’re more supportive 
toward each other. …They’re checking on each other and they talk about it when 
they’re together for their socials. …and they’re making sure that they get their 
screening done. [I37, Fam7] 
 
A recurrent theme in the interviews of both carriers and non-carriers was the importance 
of being available to and supportive of those at high risk for cancer.  One non-carrier 
commented thus: “I think it has made our family a lot closer. We are very close with my 
mother’s siblings and I think it is because, every day, it could be anybody. You just need 
to be there for them.” [I1, Fam6]  
 
From a practical knowing perspective, living through multiple bouts of cancer with a 
parent and providing care for them during the terminal stage can enhance or weaken 
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family ties. One non-carrier who had assisted with the cancer care of both parents 
perceived a positive change in relations with his siblings. 
 
There’s only the three of us siblings and you kind of lean on each other more now 
that our parents are gone. You keep closer contact and involved in each other’s 
life more than you would normally if you didn’t know about the others risk [for 
cancer]. [I18, Fam5] 
 
Cancer can also have negative repercussions for family connectedness when the early 
years have been emotionally traumatic due to a parent’s experience with cancer. The 
children may develop a strong sense of self-sufficiency that, to a degree, runs counter to a 
perceived need for openness. One non-carrier reflected upon the time when his mother 
experienced multiple bouts of cancer. This male participant perceived that family 
communications were compromised and have had pervasive, lifelong effects on all of the 
children.  
  
We sorted things out for ourselves but as a result you know became very separate 
from each other. Home was not a place necessarily of security, there was always 
that doubt there. …We all became very independent. …We are all good people 
but as a result we are not very close. [I2, Fam2A] 
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Early deaths of multiple family members also could mean that there are less people to 
provide support. As more and more relatives succumb to the disease, there is not only a 
diminishing support base but also an erosion of family connections.  
 
I didn’t have a lot of awareness of cousins of my father who became ill because I 
had lost that connection with them. …those people are strangers. …I thought it 
was interesting that they were ending up with the same problems that my father 
had. But it was not that emotional attachment to it. [I21, Fam2C] 
 
In summary, many of the study participants acknowledged the importance of being open 
about the cancer risk in the family and having access to resources and family supports in 
sharing the burden of cancer. While most were able to openly communicate, be there for 
each other and receive support, some families were challenged by the burdens imposed 
by LS.  
 
Discussion 
The current study highlights the psychosocial and emotional adjustment of 39 carriers 
and non-carriers in LS families. What is unique is that some of the carriers and non-
carriers had been having screening/surveillance and living with the risk of and/or cancer 
for almost 20 years prior to the availability of genetic testing. Very few studies have 
examined how individuals adjust in the long-term to hereditary cancer [3,14,15,26,45]. 
Most studies have focused on psychological outcomes for individuals immediately or in 
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the early months following genetic testing as opposed to how families are adjusting to 
their high cancer risk over time. 
 
The current study provides informative insight into key personal and family 
strengths/challenges that may facilitate/impede the adjustment of carriers and non-
carriers. The findings highlight the complexity of living in families with a strong history 
of hereditary cancer and the interactive impact of individual and family factors on 
adjustment. Following confirmation of LS, most individuals strive to be positive in facing 
the uncertainties associated with hereditary cancer. This attitude, although challenging to 
maintain at times, did enable most study participants to deal with cancer risk, the 
development of cancer, and recommended screening and treatment.  
 
Despite deliberate efforts to maintain a positive attitude, some participants struggled to 
adjust to the constant challenges imposed by new cancer episodes in the self or other 
family members. These findings concur with those of others who assert that there are 
challenges to long-term adjustment in families with hereditary cancers [3,41,46]. 
Nevertheless, there were a few instances where individuals who were diagnosed with 
cancer several times displayed incredible resilience. Previous research findings have also 
documented how a strong sense of resilience helps some family members adapt to 
hereditary disease [46] and cancer [47,48]. 
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Similar to the findings from other studies, the current study suggests that the major 
challenges for family members include adjusting to being a carrier or non-carrier for LS 
[26,31,33] dealing with cancer in the self and/or others [33] and worrying about other 
family members who may be at risk [32,33]. For the carriers, the emotional toll of 
waiting for cancer to surface for the first time or to recur oscillated in response to one’s 
inner strength and the perceived supportiveness of family and others. This finding 
supports the growing body of qualitative evidence on the psychosocial and emotional 
implications of living in families with hereditary cancer [3,31-33,49,50].  
 
The findings also provide data on how carriers who have developed cancer one or more 
times are managing in the long-term, an area identified by others as lacking research [27]. 
Those who had experienced cancer had already confronted the reality of what it means to 
be a LS carrier. Despite the implications, most strived to maintain a positive attitude in 
facing the diagnosis and treatment. However, encounters with cancer served to remind 
some of their high-risk status and the possibility of future bouts. 
 
Non-carriers are not spared the emotional and psychosocial burdens associated with a 
strong cancer presence in families. In the present study, this was especially evident when 
a parent experienced and survived multiple cancers during the children’s early years. 
Previous authors have identified that non-carriers can be burdened by caring for others 
with cancer and worrying about others at-risk [31,33]. In fact, just being a member of a 
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family with hereditary cancer can create burden, a sense of loss and isolation for non-
carriers [31].  
 
A key finding is that hereditary cancer not only impacts the individual but also has 
implications for immediate and extended families. This finding is supported by other 
authors [3,26,32,33,49]. Family relationships are impacted in diverse ways. Some 
families are able to maintain close relations or strengthen family ties while others 
experience distancing and a weakening of relationships. Other researchers have noted the 
variable impact that genetic conditions can have on family relationships [3,4,31-34]. 
 
The current study also highlights how family supports may buffer the overall burden of 
LS. Having someone to share experiences with plays an important role in managing a 
multitude of issues that can surface following confirmation of cancer risk. Both carriers 
and non-carriers in the current study acknowledged the need for support to help them deal 
with the uncertainty and realities of cancer. The importance of family support in adjusting 
to hereditary cancer has been reported previously [3,16,30] and family support and 
encouragement may play roles in adherence to recommended screening [51,52]. 
 
Family members, particularly carriers, have to deal with unique challenges concerning 
future generations, a concern highlighted in other studies [3,4,32,33,50]. Many members 
are burdened by the possibility of their children testing positive and then having to endure 
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screening/treatment. The level of worry and concern fluctuates back and forth from the 
self to the children and other family members. 
 
In conclusion, the presence of LS has implications for carriers, non-carriers and children 
within families. All family members must adjust to living with hereditary cancer. Family 
dynamics play a key role in buffering the challenges of effective disease management. 
Hereditary cancer has variable impact on family relations.  
 
Despite the limitations of a small sample size and the inherent biases in having 
participants recall how they experienced and responded to various events and situations, 
the findings provide practical insight into the long-term personal and family implications 
of hereditary cancer. The findings suggest that the variant experiences of carriers, non-
carriers and their families are influenced by diverse personal and familial factors. 
 
Clinical and Policy Implications 
This study has examined the long-term psychosocial and emotional impact of LS on 
individuals and families. By referencing a qualitative data base derived from carriers and 
non-carriers, we argue that most family members will need support that extends far 
beyond the immediate genetic testing period to successfully integrate the burden of 
multiple demands [3]. Other authors have questioned the adequacy of health care system 
support for non-carriers and unaffected carriers of hereditary cancer and recognize the 
importance of providing care even in the absence of a cancer diagnosis [41].  
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Ideally, genetic counseling should explore the psychosocial and emotional impact of 
hereditary cancer and assist individuals and families in adopting effective strategies to 
lessen the burden of the disease. The variation and complexity of personal experiences 
and experiential knowledge from living in families with LS necessitates a family-
centered approach to the provision of genetic services. Further, psychosocial and 
emotional adjustment over time must be considered, particularly when cancer emerges in 
the self and/or others. Adjustment must also be assessed in terms of the impact on 
adherence to recommended screening and treatment. The barriers to and facilitators of 
screening in this population have been documented [2]. The findings suggest a complex 
interaction of the emotional and physical burden of managing LS and the practical 
demands of everyday living [2]. Given the documented benefits of screening in this 
population [11], it is imperative that ongoing assessment of the psychosocial and 
emotional impact be inclusive of implications for effective disease management. 
 
The quality of family relations and the availability of supports to share the cancer burden 
are important factors influencing overall adjustment to LS. Assessing family functioning 
can help shed light on an individual’s level of awareness and acceptance of high-risk 
status [32]. Knowledge gained from this assessment can help genetics personnel identify 
those with strong and weak family support systems [49]. Strong family systems suggest 
the presence of sufficient resources to help buffer stress and facilitate adjustment. 
Conversely, weak family systems should indicate to genetics personnel that there is a 
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need to provide additional cognitive and emotional support regarding risk and disease 
prevention.  
 
Being at risk for LS is a condition that affects the individual and family with both 
requiring support over time. Genetic testing for LS is one event along a continuum of 
lifelong disease management. The years prior to and following the event are very 
significant to families in terms of psychosocial and emotional impact and require further 
study and exploration [46] The concerns for future generations suggest the need for 
supportive interventions. Health care providers need to understand that even though 
individuals may accept and adjust to their carrier status, they can experience periodic 
challenges over the long-term.  
 
Importantly, LS has implications for public health policy [53]. The ultimate plan should 
be to provide a coordinated system of health care services that includes continuing 
assessment and support well beyond the immediate genetic testing period. Formal health 
care supports must be readily available particularly when existing personal and family 
resources are inadequate to facilitate adjustment to the hereditary condition.  
 
In order to ensure that health care services are tailored to meet individual and family 
needs, clinical monitoring tools should be in place to evaluate adjustment to the evolving 
psychosocial and emotional challenges of hereditary diseases. Our team has developed a 
reliable and valid scale that is capable of capturing how carriers and non-carriers are 
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adjusting to hereditary cancer at any point in time [1]. The scale is designed to elicit data 
on the psychosocial and emotional impact (personal and family strengths/challenges) of 
receiving confirmation of a carrier or non-carrier status, and the importance of being part 
of a supportive family network. Preliminary results indicate that there is a core group of 
individuals in all families who are struggling to adjust. The significance of the family 
environment and dynamics in members’ adjustment to LS was also confirmed.  
 
In conclusion, the supportive and informative roles of genetic counselors and other health 
care providers, knowledgeable about managing LS, will be critical in promoting 
successful psychosocial adjustment and a reasonable quality of life. 
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Background: The presence of Lynch syndrome (LS) can bring a lifetime of uncertainty 
to an entire family as members adjust to living with a high lifetime cancer risk. The 
research base on how individuals and families adjust to genetic-linked diseases following 
predictive genetic testing has increased our understanding of short-term impacts but gaps 
continue to exist in knowledge of important factors that facilitate or impede long-term 
adjustment. The failure of existing scales to detect psychosocial adjustment challenges in 
this population has led researchers to question the adequate sensitivity of these 
instruments. Furthermore, we have limited insight into the role of the family in promoting 
adjustment.  
Methods: The purpose of this study was to develop and initially validate the 
Psychosocial Adjustment to Hereditary Diseases (PAHD) scale. This scale consists of 
two subscales, the Burden of Knowing (BK) and Family Connectedness (FC). Items for 
the two subscales were generated from a qualitative data base and tested in a sample of 
243 participants from families with LS.  
Results: The Multitrait/Multi-Item Analysis Program-Revised (MAP-R) was used to 
evaluate the psychometric properties of the PAHD. The findings support the convergent 
and discriminant validity of the subscales. Construct validity was confirmed by factor 
analysis and Cronbach’s alpha supported a strong internal consistency for BK (0.83) and 
FC (0.84).  
Conclusion: Preliminary testing suggests that the PAHD is a psychometrically sound 
scale capable of assessing psychosocial adjustment. We conclude that the PAHD may be 
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a valuable monitoring tool to identify individuals and families who may require 
therapeutic interventions.  
 
Background 
Lynch syndrome (LS) is an autosomal dominant disease characterized by the 
development of colorectal (CRC) and extracolonic cancers [1]. Individuals living with LS 
may be faced with cancer onset in themselves and other family members, lifelong cancer 
screening, extensive treatment regimes and early deaths of family members. 
Confirmation of LS through predictive genetic testing can bring a lifetime of uncertainty 
to an entire family as members adjust to living with an indeterminate or evolving disease 
state. The research base on how individuals and families adjust to genetic-linked diseases 
following predictive genetic testing has increased our understanding of short-term 
impacts but gaps continue to exist in knowledge of important factors that facilitate or 
impede long-term adjustment. 
 
In studies focusing on the impact of genetic-based diseases, the adjustment construct 
assumes many forms. Psychological/psychosocial adjustment is used interchangeably 
with psychological/psychosocial functioning, impact, distress, consequences and 
outcomes, among others. What is evident from a review of the scientific literature is a 
lack of consensus on how psychological adjustment is defined and operationalized [2]. 
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Quantitative studies that focus on hereditary cancer have primarily assessed short-term 
psychological functioning (i.e., cancer specific distress, anxiety, and depression) by using 
such standardized scales as the State-Trait Anxiety Inventory [3-9], Impact of Events 
[3,5-8,10], Hospital Anxiety and Depression Scale [5,9,10], and the Center for 
Epidemiologic Studies Depression Scale [6-8]. The evidence suggests that individuals 
who are part of LS families are not distressed (intrusive thoughts about cancer, anxiety 
and depression) in the short-term post-genetic testing. Prospective studies monitoring 
changes in psychological functioning during genetic testing show slight elevations in 
carriers distress levels immediately post-testing which return to baseline levels within a 
year, but decrease immediately for non-carriers and remain relatively stable over time 
[3,4,6,11]. Investigations of impact for longer periods revealed no differences in 
psychosocial outcomes between carriers and non-carriers at three [5,12] or five years 
post-testing [13]. The conclusion of meta-analyses and literature reviews is that genetic 
testing for hereditary cancer causes minimal psychological consequences [14-17]. 
 
Absent from this quantitative research base is prospective data on long-term psychosocial 
adjustment. Specifically, there is minimal consideration of the psychosocial and 
emotional impact of living with hereditary cancer, personal and family challenges over 
time, and the role played by family functioning and supports in reducing the impact of 
hereditary cancer and facilitating adjustment. In 2004, our research team administered a 
battery of standardized and researcher-developed scales to a convenience sample of 120 
carriers and non-carriers from LS families in Newfoundland and Labrador at different 
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times post-genetic testing (i.e., 0.1 to 9.2 years). Baum and colleagues theoretical model 
of stress and adaptation (1997) [18], previously described by Esplen et al. (2007) [8], was 
used to guide data collection. Table 3.1 presents a summary of the objectives, methods 
and select findings of this initial survey. Study findings revealed that most respondents 
were not psychologically distressed (anxious, depressed, intrusive and avoidant thoughts) 
from being involved in genetic testing for LS, did not convey worry/concern about cancer 
risk for the self/others, were part of healthy functioning families with adequate internal 
strengths, were satisfied with available social supports, relied equally on emotion-focused 
and problem-focused coping, and were satisfied with valued aspects of life (family, 
health and functioning, psychological spiritual and social/economic). Although most 
individuals seemed well adjusted, a subgroup had elevated distress levels, compromised 
family functioning and lower quality of life. 
 
There is additional support from the literature that a small, but significant, group of 
individuals experience adjustment problems and may be classified as having borderline 
distress [8,13,17]. Problems with psychological functioning may negatively impact long-
term adjustment, particularly adherence to recommended screening protocols crucial for 
the prevention and early detection of cancer. Importantly, the evidence suggests that 
individuals with greater social supports and who belong to families with open 
communication are more likely to follow recommended protocols [19-21], have less 
psychosocial distress [22-24] and adjust better over the long-term [10]. 
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Table 3.1:  Objectives, instruments used and results of two preliminary studies 
undertaken prior to the current study 
Study Objectives Instrumentation Results 
Phase I: 
Survey 
1) to investigate psychosocial 
and behavioral impact of 
genetic testing (GT) process for 
at-risk individuals in LS 
families 
Standardized scales (Impact of 
Events Scale [28], Center for 
Epidemiologic Studies Depression 
Scale [29], State-Trait Anxiety 
Inventory [30], McMaster Family 
Assessment Device [31], Family 
Hardiness Index [32], Quality of 
Life Index [33], Social Support 
Questionnaire [34], Ways of 
Coping Questionnaire) [35]; 
researcher-developed items 
(medical history, worry/concerns, 
demographics, cancer experiences, 
reaction to & disclosure of results, 
screening & healthy living) 
Sample characteristics: 
 
- mean age of 47.4 (SD = 12.9), 
range 22 to 78 years 
- female (57.5%), carriers 
(51.7%) of intron 5 splice site 
mutation (93.3%) and 
unaffected (77.5%) 
- average of 6 years post-
genetic testing 
2) to examine key factors (i.e., 
age, gender, education, 
supportive relationships, 
familial & personal cancer 
history, CRC knowledge, 
satisfaction with GT decision, 
time since GT) associated with 
difficulties in psychosocial and 
behavioral adjustment (reaction 
to GT results, perception of 
risk, willingness to disclose and 
to whom) in individuals 
affected/unaffected with cancer 
Key findings: 
 
- over 33% had moderate to 
severe avoidance/intrusive 
thoughts post-GT; 
- small percent above clinical 
cut-off score for depression and 
anxiety 
- small percent with quality of 
life issues and lower family 
functioning (role execution & 
communication) 
- no significant impact for time 
since GT, gender, age, carrier 
or cancer status 
Phase II: 
Qualitative 
1) to explore meanings of 
genetic testing for individuals 
at risk for colorectal and 
related-cancers in LS families 
Semi-structured interviews 
focused on: familial cancer 
experiences (exposure in 
close/distant members, first aware 
of hereditary link, perceived risk 
for self, screening/healthy living 
motivation) and pre/post GT 
(decision-making pre and post 
testing, experience with genetic 
counseling, reaction to GT results, 
understanding risk for self/others, 
impact on family, role/importance 
of supports, adjusting to status & 
experiences with health care) 
Constructs: 
 
- Living in families with a 
strong history of hereditary 
cancer (familial cancer context 
& emergence of hereditary link) 
- Becoming aware of genetic 
testing and living the process 
(decision-making, reactions to 
results, understand risk, 
supportiveness of genetic 
counselors, disclose results) 
- Struggling to adjust 
(personal/family challenges, 
family dynamics/support, 
barriers/facilitators of 
adjustment) 
 
2) to understand psychosocial 
and behavioral impact of 
genetic testing for carriers and 
non-carriers of LS 
 
3) to use emergent data to 
improve existing counseling 
programs 
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With the sensitivity and specificity of standardized scales for detecting and monitoring 
psychosocial adjustment in this population questioned [4,14], Read et al. (2005) [25] 
developed the Psychological Adaptation to Genetic Diseases (PAGIS) scale to evaluate 
the efficacy of genetic counseling and identify individuals requiring additional support. 
These researchers propose that psychological adaptation to genetic information is a 
multidimensional phenomenon comprised of non-intrusiveness, support, self-worth, 
certainty and self-efficacy. While the PAGIS demonstrated acceptable internal 
consistency and content validity in preliminary testing, there is no further reference to its 
use in subsequent studies. The Multidimensional Impact of Cancer Risk Assessment 
(MICRA) questionnaire [26] was developed to measure positive and negative responses 
to genetic testing for cancer. The MICRA was initially validated among women at risk 
for breast cancer but, to our knowledge, has not been used in subsequent studies. Despite 
these disease-specific scales, there is no empirical evidence suggesting that they are 
capable of monitoring how well individuals adjust to genetic-based diseases in the short-
and long-term [27]. 
 
Critical appraisal of the research evidence on adjustment challenges for LS families from 
studies using quantitative versus qualitative methodologies can lead to very different 
conclusions. Reliance on qualitative methods helps researchers identify areas of 
psychosocial impact that have implications for affective and behavioral outcomes. The 
evidence suggests that certain individuals have difficulty adjusting in the short- and long-
term following confirmation of hereditary cancer [36-40], feel burdened about 
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communicating genetic risk information to family members [40], worry about cancer risk 
in others [36,37], perceive that health care system supports post-genetic testing are 
inadequate [38,39], struggle to adhere to recommended screening protocols [38,39] and 
experience difficulty in coping with cancer in the self/others [37]. 
 
Following the 2004 survey, our research team designed a grounded theory study to 
explore the meaning of genetic testing for individuals (N=39) in LS families and develop 
a greater understanding of psychosocial and behavioral impacts for confirmed carriers 
and non-carriers. Data collection spanned the years 2004 to 2007. Purposive samples 
were recruited from 15 family groupings: (a) 2004 survey respondents with an interest in 
further research (n=22), (b) additional individuals from families with the intron 5 splice 
site mutation to augment evolving family, carrier/non-carrier or affected/non-affected 
themes (n =10), and (c) individuals from families with the more recently identified exon 
8 deletion to ensure comparability of experiences in families with the intron 5 splice site 
mutation families (n=7). Details on the sample and data analysis have been described 
elsewhere [39]. Semi-structured schedules guided data collection via face-to-face 
interviews. A second interview confirmed the interpretive summaries constructed from 
each transcript, augmented gaps in the data and corroborated conceptual categories and 
properties. Table 3.1 summarizes study objectives, methods and key findings. 
 
The conceptual model “Confronting and Accepting the Challenges of Living in Families 
with Genetic-Linked Diseases” emerged from analysis of the qualitative data. The model 
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broadly conjectures that the situational and experiential contexts are important forces 
influencing how well individuals accept the hereditary link to cancer, are motivated to 
become involved in genetic testing, and adjust to living with a confirmed presence of LS 
in the family in the short- and long-term. The struggling to adjust construct focuses on 
psychosocial and behavioral adjustment in LS families. The findings suggest that while 
most individuals acknowledge the importance of knowing about their cancer risk, some 
are burdened by having to manage LS over time (i.e., struggle to adhere to recommended 
screening) and having to deal with cancer episodes in the self and/or others. Importantly, 
the impact of LS is not limited to carriers but extends to all family members. Family 
functioning and openness of communications seem critical in helping individuals deal 
with the ongoing challenges. Finally, the findings provide further support for the premise 
that some individuals in these families experience difficulty adjusting in the short- and 
long-term and, at times, struggle to effectively manage their disease. 
 
Based on the research literature and quantitative and qualitative findings from the two 
projects conducted by the research team, it was concluded that reliable and valid clinical 
tools capable of identifying subgroups of individuals, as well as their families, who may 
be at-risk for psychosocial and emotional challenges post-genetic testing are needed for 
use in genetics clinics. Monitoring tools are needed to assess adjustment to LS (i.e., 
positive affect and well-being, motivation to follow recommended protocols and modify 
health behaviors, and the buffering impact of supports). It was also evident from the 
literature and our findings that health care providers tend to not only have limited insight 
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into the extent of individual and family burden posed by genetic-based diseases but also 
fail to understand the level of support that might be needed to mitigate long-term effects. 
 
In summary, emphasis on short-term outcomes, without thorough consideration of the 
social and familial contexts, can limit our understanding of long-term psychosocial 
adjustment. We argue that adjustment to hereditary cancer is broader than psychological 
outcomes and is an evolving process that ebbs and flows in response to changing personal 
and family experiences in the management of long-term cancer risk and emergence of 
cancer in the self and/or others. Personal and/or family experiences can facilitate or 
impede adjustment. 
 
Purpose 
The purpose of the current study was to develop and initially validate a tool for 
monitoring long-term psychosocial adjustment. Using the data generated from a 
grounded theory study, the Psychosocial Adjustment to Hereditary Diseases (PAHD) 
scale was developed as part of an ethically approved program of research. The PAHD is 
designed to assess the personal and family burden of LS and the perceived role of family 
in buffering its impact. The specific objectives for this component of the larger project 
are to: (a) test the feasibility of using the PAHD scale under variant conditions, (b) reduce 
item numbers, (c) validate subscale and overall scale structure, and (d) examine scaling 
(rating) methods. 
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Methods 
The study was conducted in three phases. Phase I consisted of item generation and 
refinement. Phase II consisted of a pilot study designed to generate data for preliminary 
assessment of the psychometric properties of the PAHD scale. Phase III was designed to 
generate additional data to facilitate final item selection and initial scale validation. 
 
Phase I: Scale Development 
Interview transcripts from the grounded theory study provided the data base for scale 
development. The grounded theory method facilitated theoretical construct identification 
in such a manner that operational indicators defining the properties of each construct 
could be used to generate items. Initially, data matrices were created for the struggling to 
adjust construct by collating all data from the interviews into relevant descriptors of 
properties and re-writing the text until a clear decision trail emerged. Two dominant 
themes emerged from these analyses - one focusing on psychosocial adjustment and the 
other on behavioral adjustment. The psychosocial adjustment data matrix provided the 
content for item generation for the PAHD. 
The approach taken to item generation and refinement consisted of several steps which 
are summarized in Table 3.2. The first step involved item generation and refinement. The 
focus was on identifying potential stems, reducing the number of stems and reworking 
and finalizing the text. The items were grouped into two subscales based on theoretical 
content. The first subscale dealt with personal burden issues (i.e., psychosocial distress 
and emotional well-being), and the second with family dynamics and the importance of 
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openness and supports. At the second step, efforts focused on selecting the best rating 
scale format to use with this population. Following consideration of multiple selection 
options, the research team decided to use one rating scale (not at all, a little bit, 
moderately, quite a bit, extremely). The fifth and final steps focused on assessing the 
scale’s readability and subjecting it to content validation. The readability level of the 
PAHD was at an acceptable level and genetic counselors and individuals from LS 
families validated the content of the PAHD, as well as the usefulness of the rating scale. 
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Table 3.2:  PAHD scale development 
Item stem 
identification 
A four-member research team was responsible for item generation and refinement. Initially, the team 
became immersed in the data matrices of the struggling to adjust construct. Independent raters created 
a profile of frequency and priority ratings of construct properties and descriptors (e.g., dwelling on 
carrier status, positive outlook, concern for young family members, importance of openness, strain on 
relations, emotional burden of suffering & death) by participant and group. Team members used these 
profiles to generate item stems for 5 groups and the principal investigator validated the process. At 
this stage, the team had 59 potential items. 
Item stem 
reduction 
Multiple drafts of items for the scale were reviewed and modified by the researchers. Team meetings 
were held frequently to collate, prioritize and refine item stems for potential scale inclusion (emphasis 
on conciseness, avoidance of negative wording, ambiguous terminology, jargon, value-laden words 
and double-barreled questions). A final set of 17 items were identified for potential inclusion in the 
PAHD scale. 
Rating scale 
development 
Initial rating scales focused on the frequency of occurrence (never, rarely, sometimes, often, or almost 
always), and ‘the importance/difficulty/receptiveness of’ or ‘how 
satisfied/concerned/confident/certain one was with’ select events/situations (not at all, a little bit, 
moderately, quite a bit, extremely). The multiple selection options made things cumbersome and 
confusing. The decision was made to rework the items and use one rating scale. Despite recognizing 
that a 5-point scale might not be sufficient for maximum reliability, the group consensus was that it 
would be difficult to devise unambiguous additional ordinal adjectives. 
Scale 
readability 
Several tools (i.e., Flesch-Kincaid Grade Level and Flesch Reading Ease, Fog index and SMOG) were 
used to assess the PAHD’s reading level at less than or equal to Grade 10. Although a grade less than 
10 is recommended to ensure maximum reading ease and material comprehension, the PAHD is 
developed to assess the experiences of individuals who have had predictive DNA testing. These 
individuals have had repeated exposure to terms such as LS, hereditary non-polyposis colorectal 
cancer, carriers/non-carriers, inherited, generations, genetic and geneticist/genetic counselor. These 
polysyllabic words and others are used frequently throughout the scale which does increase the final 
readability score. 
Content 
validation 
First, two genetic counselors (GCs) who work with individuals during the genetic testing process 
reviewed the PAHD. A brief written synopsis of the conceptual model and construct definitions, along 
with a copy of the scales, were given to the GCs to prepare them for this task. Input was requested on 
item content relevancy (extremely, moderately, slightly, or irrelevant) in terms of its ability to 
measure the properties of targeted constructs, and effectiveness (very, moderately, poorly or not at all 
effective) of the 5-point Likert rating scale for ease of item rating. Minor changes to select items were 
made based on their recommendations. Second, the PAHD was administered to individuals (carrier & 
non-carrier) who had participated in the survey and qualitative studies. Respondents were asked to 
comment on item clarity/relevancy, and rating scale usefulness. No changes were made at this stage. 
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Phase II: Pilot Study 
Using a descriptive correlational design with longitudinal components the PAHD scale 
was initially tested in individuals from LS families. The approach to scale testing was 
based on the work of Ware and Gandek (1998) [41], a method used by others [42,43]. 
 
Methods 
The pilot study was designed to assess the integrity of subscale and scale structures, item 
clarity and difficulty, time required for completion and the feasibility of using different 
administrative methods. It also provided data for a preliminary assessment of the PAHD 
scale. Following creation of a descriptive profile for each item (i.e., frequencies, means, 
standard deviation, skewness and missing data), a correlation matrix was generated and 
the strength and significance of inter-item correlations assessed. A summary table was 
constructed of inter-item correlations falling within set cutoff ranges (i.e., >.40 and .30 to 
.40) which was the primary basis for initial subscale item selection. The final steps 
included factor analysis and reliability analysis using Cronbach’s alpha. 
 
Population and Sample 
The target population was individuals at 50% risk for inheriting LS who had participated 
in genetic testing and informed of their carrier status. Survey respondents were recruited 
from families attending the Provincial Medical Genetics Program of Newfoundland and 
Labrador (PMGP-NL). Three large pedigrees with MSH2 mutations on intron 5, exon 8 
or exon 4 to 16 have been identified with 272 carriers and 295 non-carriers confirmed 
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and entered into a Cancer Screening Data Base. This data base provided the resource for 
subject recruitment for the pilot study which occurred between February and June of 
2008. Of the 120 individuals contacted, 75 (45 carriers and 30 non-carriers) completed 
the survey, resulting in a 62.5% response rate. 
 
Procedure 
Ethical approval of the study protocol was granted by the Human Investigation 
Committee, Faculty of Medicine, Memorial University as well as Eastern Health where 
the PMGP-NL is located. Telephone contact was initiated with potential respondents to 
inform them about the study and ascertain their willingness to receive additional 
information. Consenting individuals were forwarded packages consisting of a cover 
letter, a brief summary of the study, two consent forms and the survey instrument. 
Following receipt of consent, a follow-up telephone call was made to determine the 
preferred mode of participation (face-to-face, telephone or self-administered) and to 
schedule a mutually agreed upon time for survey completion. 
 
Preliminary Results 
Importantly, data completeness was similar for all three methods of PAHD 
administration, indicating that it is possible to administer this scale under variant 
conditions. Preliminary findings indicated that the two subscales appeared to be sensitive 
enough to measure a range of factors influencing psychosocial adjustment. For most 
items, there was evidence of fair spread across the response choices. Although factor 
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analysis indicated that item sampling was less than desired, no further analyses were 
pursued until further subject recruitment. 
 
Post-Pilot Findings 
Following recruitment of additional respondents, the PAHD subscale structure was 
reexamined. The items comprising the two subscales were merged with items from the 
subscales of the Hereditary Diseases and Genetic Testing (HD-GT), a second scale 
developed by the research team to assess the impact of the genetic testing process (pre, 
during and post receipt of results), and a correlational matrix generated. It was anticipated 
that this approach would help the research team determine if meaningful divisions existed 
between the subscales of the HD-GT dealing with psychological and emotional issues 
from engaging in genetic testing compared to those of the PAHD which focus on 
assessment of more long-term effects. The correlation matrices confirmed the uniqueness 
of the PAHD subscales and identified additional items not loading on any HD-GT 
subscales but theoretically similar in content to PAHD items. 
 
The final PAHD scale (Appendix 1) contained two subscales with 17 items (Table 3.3). 
The Burden of Knowing (BK) and Family Connectedness (FC) subscales are in line with 
the psychosocial and emotional component of the construct struggling to adjust. The 
conceptual definition highlights the importance of capturing: (a) the perceived personal 
and/or family burden following confirmation of LS, and (b) the role played by family 
supports in promoting status acceptance and buffering the impact of challenges posed by 
 
 
99 
 
the disease. The BK scale is comprised of 10 items that recognize the personal and family 
aspects of adjustment to hereditary cancer with higher scores reflecting lesser burden. 
Additional items from the HD-GT scale address how the stress of cancer in younger 
family members may impact family relations (BK19_R) and how regular screening may 
heighten cancer worries (BK20_R, BK27_R). 
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Table 3.3:  Item descriptive statistics for Burden of Knowing (BK) and Family 
Connectedness (FC) scales (N = 243) 
Scale & Items X SD Missing (%) Response Values Frequency 
0 1 2 3 4 
Burden of Knowing (BK) 24.8 8.4 9.5% 
     
• Dwelling on carrier status (BK11_R) 3.1 1.1 0.8 5 24 36 65 111 
• Difficulty modifying screening regime (BK14_R) 2.8 1.4 1.6 28 17 41 34 119 
• Concerns with non-acceptance by others (BK15_R) 3.4 1.2 2.5 13 14 12 27 171 
• Difficulty dealing with young people (BK17_R) 1.8 1.4 3.3 59 43 59 28 46 
• Worry about young people’s future (BK18_R) 1.4 1.3 1.2 80 58 49 39 14 
• Stress of cancer alters family relations (BK19_R) 2.8 1.3 1.6 17 33 39 40 110 
• Screening reminder of personal risk (BK20_R) 2.2 1.5 1.2 50 37 44 39 70 
• Concerns about impact on family relations 
(BK24_R) 3.3 1.2 0.4 13 15 24 25 165 
• Worry about burden of cancer on family (BK25_R) 2.3 1.4 0.8 30 44 54 49 64 
• Screening heightens cancer worry (BK27_R) 1.9 1.5 0.8 63 46 41 45 46 
Family Connectedness (FC) 20.4 5.6 4.5 
     
• Encourage young people to talk about cancer 
(FC16) 3.0 1.1 1.2 10 18 49 60 103 
• Feeling supported facilitates acceptance (FC21) 2.9 1.2 0.4 13 21 41 77 90 
• Easy to seek help from family (FC22) 3.0 1.2 0.8 13 18 34 67 109 
• Important to openly discuss family cancer (FC23) 3.4 0.8 0.4 0 8 27 62 145 
• Caring for others promotes personal acceptance 
(FC26) 2.3 1.4 1.6 37 31 50 66 55 
• Relieved by availability of genetic testing (FC28) 2.9 1.2 1.6 10 21 42 66 100 
• Supportive others promotes healthy behaviors 
(FC29) 3.0 1.1 0.4 11 16 33 78 104 
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Comparatively, the seven-item FC scale assesses family connectedness with higher 
scores reflecting the importance of having open discussions and access to resources to 
handle the challenges posed by LS. Additional items from the HD-GT scale address 
feelings of relief concerning the availability of genetic testing (FC28) and the role of 
supportive others in promoting acceptance of healthy behaviors (FC29). Two items 
dealing with emotional well-being (BK12) and not dwelling on the hereditary cancer 
(BK13) failed to load on either subscale but were retained as test items for future scale 
administrations. 
 
Phase III: Initial Validation 
Ongoing recruitment and data collection continued between July 2008 and July 2010. 
Data were collected by face-to-face interviews, telephone interviews and self-
administered surveys. Of the additional 253 individuals contacted, the scale was 
administered to another 168 participants. In total, 373 individuals agreed to receive study 
materials during the two phases giving a total sample size of 243 (140 carriers and 103 
non-carriers of LS) and a response rate of 65.1%. 
 
Study respondents were mostly females (63.8%) and from families with a confirmed 
MSH2 gene mutation (92.6%). Of the MSH2 mutations (intron 5 splice site, exon 8 
deletion or exon 4-16 deletion), the dominant type was the intron 5 splice site (62.1%). 
The remaining participants had mutations in either MLH1 (6.6%) or MSH6 (0.8%). The 
mean age was 48.80 (SD =13.60), with a range of 19 to 83 years. Most participants were 
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carriers (57.6%) but unaffected by cancer at the time of the study (72.8%). Although 
study respondents and non-responders were similar with regard to gender (χ2 (1, 
N=)=2.08, p>0.05), non-responders tended to be non-carriers (χ2 (1, N=)=4.79, p<0.05) 
and younger (t (361)= -2.63, p<0.01) than respondents. 
 
Data Analysis 
Data were coded and entered into the Statistical Package for the Social Sciences (SPSS) 
for analysis. Descriptive statistics were used to create a profile of respondents’ scores on 
all study scales. The Multitrait/Multi-Item Analysis Program-Revised (MAP-R) assessed 
how well the PAHD met Likert scaling assumptions [44]. At the first step, the assumption 
concerning the appropriateness of using particular items to create a summative score 
(approximate equivalence of means and variances, use of all response choices in the 
rating scale, amount of missing data, and approximate symmetry in response distribution) 
was assessed. At the second step, a multitrait/multi-item correlation matrix was generated 
to assess three additional assumptions (linearity, item-convergent validity and item-
discriminant validity). At the third step, subscale scores were assessed in terms of ceiling 
and floor effects, approximate symmetry, internal consistency and inter-correlations. 
Finally, factor analysis examined the construct validity of the 17-item PAHD scale. The 
appropriateness of the factor analytic model was tested using the Kaiser-Meyer-Olkin 
(KMO) measure of sampling adequacy and Bartlett’s test of sphericity. Principal 
component and maximum likelihood analysis were the factor extraction methods. The 
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scree test was used to determine the number of factors to retain. The preferred rotation 
method was orthogonal using varimax rotation. 
 
Results 
Data Quality and Item-Level Summated Scale Assumptions 
Data Quality 
Item descriptives for the PAHD scale are displayed in Table 3.3. Missing data for 
individual items were random and minimal, ranging from 0.4% to 3.3%. Although there 
is no consensus on what constitutes extensive missing data (from 10%-40%) on any 
given item or variable, it is generally agreed that what is more important is whether the 
pattern is systematic or random in nature [45]. 
 
The majority of respondents had complete data for the two subscales. The percent of 
respondents with complete data ranged from 90.5% for BK to 95.5% for FC (data not 
shown). The minimum and random amount of missing data for this study suggests that 
overall the scale items were not difficult to understand or interpret [41]. 
 
All response choices were used for most items (94.1%). The data also depict variability 
across the rating scale and approximate a symmetrical distribution. The subscale items 
with minimal to no use of certain response choices were expected. For example, most 
individuals are expected to attach high importance to having family members talk openly 
about the high cancer risk (FC23). 
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Item-Level Scaling Assumptions 
Items means and standard deviations within each subscale are approximately equivalent 
(Table 3.3). There are important exceptions, however, which require further elaboration. 
In the BK subscale, items 17, 18 and 27 have lower mean scores and greater variance 
than the remaining items. This finding is expected given that these items are more 
focused on personal worries and interaction difficulties. The higher mean scores and 
lower variances observed for items 11, 15 and 24 were also expected since their content 
focuses on the personal and family implications of knowing one’s carrier status and 
dealing with LS. Similarly, the higher score and lower variance observed for item 23 of 
the FC subscale was also expected as most individuals attach importance to open 
discussion of high cancer risk among family members. 
 
Scale Level Assumptions 
Item Internal Consistency 
Table 3.4 outlines Pearson item-scale correlations corrected for item overlap [41,46]. 
Item-scale correlations were used to examine the relationship of each item to its 
hypothesized scale (i.e., internal consistency). Correlations for all items within their 
respective scales are larger than correlations between items and competing scales. In 
addition, all item-scale correlations are 0.42 or larger indicating a substantial and 
satisfactory item internal consistency [41]. 
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Table 3.4:  Factor scores and final item to scale correlations 
Scale item Factor 1 Factor 2 BK§ FC§ 
BK11_R .620 -.121 0.58* -0.25 
BR14_R .555 -.051 0.45* -0.16 
BK15_R .516 -.080 0.46* -0.20 
BK17_R .531 -.150 0.49* -0.26 
BK18_R .562 -.412 0.55* -0.46 
BK19_R .520 -.160 0.48* -0.28 
BK20_R .583 -.218 0.55* -0.32 
BK24_R .473 -.055 0.42* -0.16 
BK25_R .612 -.188 0.56* -0.32 
BK27_R .533 -.209 0.50* -0.32 
FC16 -.263 .524 -0.36 0.46* 
FC21 -.103 .769 -0.29 0.70* 
FC22 .001 .706 -0.19 0.59* 
FC23 -.180 .798 -0.36 0.73* 
FC26 -.237 .503 -0.34 0.51* 
FC28 -.162 .537 -0.28 0.48* 
FC29 -.180 .600 -0.32 0.58* 
Abbreviations: BK = Burden of knowing, FC = Family connectedness. 
Extraction Method: Maximum likelihood; Number of factors to retain: Scree test; 
Rotation method: Varimax. 
§ Item-scale correlation corrected for overlap (relevant item removed from its scale for 
correlation). *Denotes item correlations with hypothesized scales. 
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Equality of Item-Scale Correlations 
This assumption addresses the proximity of values for all item-scale correlations within a 
hypothesized scale. The best scale contains item-scale correlations that are roughly equal 
and ideally fall within the 0.40 to 0.70 range [41]. The reader is again referred to the 
corrected item-total correlations for individual items and their subscales in the columns 
with asterisks in Table 3.4. 
For the majority of items in the two subscales, the corrected-item total correlations fall 
within an acceptable range. There are some exceptions however. The items that appear to 
be contributing more to their various scales than other items include items 21 and 23 of 
the FC subscale. These items deal with emotional content which may be responsible for 
the observed discrepancies. This finding is expected to a degree since item content is 
focused on the importance of feeling supported by family/friends in coming to terms with 
being a carrier/non-carrier and the importance of family members openly discussing the 
cancer risk. 
Item Discriminant Validity 
This assumption examines the strength of item correlations with other scales with the 
objective that each item has a stronger correlation with its hypothesized scale than with 
other related scales. Study findings are summarized in Table 3.4. Four score categories   
(-1, -2, +1 or +2) are possible for each test with the standard error of correlation setting 
the criterion. Values of a -1 and a -2 indicate that an item has failed the test of item 
discriminant validity. In this study, all item scale discriminant tests (data not shown) 
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scored +2 indicating item-scale correlations were significantly higher for the 
hypothesized scale than for a competing scale. 
 
Scale Level Descriptive Statistics 
Total subscale scores were constructed for each participant following confirmation of 
item scaling assumptions. Consideration was first given to the impact of select sample 
characteristics on subscale scores. At the second step, the properties of the subscales were 
examined with special attention given to the logic of mean and standard deviation scores. 
 
Comparability of Scale Scores 
It was hypothesized that subscale means should be approximately equal within the 
sample based on demographic and illness-related characteristics. The reader is reminded 
that the BK subscale is reversed scored. The t-test of difference and correlation tests 
assessed the impact of select factors on subscale scores. No significant effect was 
detected for carrier status, exon type, cancer presence, age or time since genetic testing 
(p>.05) (data not shown). However, females tended to report significantly higher levels 
of burden than men on the BK subscale. Women also had significantly higher mean 
scores than men on the FC subscale suggesting that women attach greater importance to 
having access to family support and resources in dealing with LS. 
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Scale Properties 
Subscale means, standard deviations, lowest and highest scores and score ranges were 
examined for both raw and transformed scores. The focus here was on the logic behind 
the distribution of subscale scores. For the BK subscale, a higher score is reflective of 
less personal and family burden associated with adjustment to hereditary cancer. Higher 
scores on the FC subscale are reflective of better family connectedness in dealing with 
the challenges posed by LS. 
 
The pattern of mean scores and standard deviations for each subscale is summarized in 
Table 3.5. The transformed mean score (62 ± 20.9) on BK suggests that participants, on 
average, reported experiencing a little to moderate amount of burden. The transformed 
mean score (73 ± 19.9) on the FC subscale suggests that respondents, on average, gave 
high ratings to having open discussions and access to family resources/supports to handle 
the challenges posed by LS. 
 
 
Table 3.5:  Descriptive statistics using transformed scores for Burden of Knowing 
(BK) and Family Connectedness (FC) scales 
Scale Mean SD Range % Missing % At floor % At ceiling 
BK 62.0 20.9 0-100 9.5 0.5 0.5 
FC 73.0 19.9 14.3-100 4.5 0.4 6.5 
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Reliability and Validity of PAHD 
Cronbach’s alpha coefficient was used to assess internal consistency. Correlations among 
the subscales are useful preliminary measures of the construct validity of the entire scale. 
Reliability ranged from 0.83 for BK to 0.84 for FC. The reliability coefficients were 
above the minimum 0.70 level suggested for group level comparisons [47]. These 
findings suggest that the two subscales have good internal consistency. 
 
The findings support the premise that each of the two subscales is making a distinct 
contribution to the overall PAHD scale. The alpha coefficients for each of the subscales 
are larger than the Pearson’s r values (data not shown). The subscales of the PAHD 
depict significant low to moderate, negative correlations with each other. That is, higher 
levels of family connectedness are associated with lower levels of personal and family 
burden in adjusting to LS. 
 
The 243 participants provided an adequate sample for conducting factor analysis of the 
17-item PAHD scale. The KMO value was 0.85 exceeding the minimally acceptable level 
of 0.6 [48]. Bartlett’s test of sphericity was also acceptable (p = 0.000), indicating the 
feasibility of using a factor model for the analysis. These two measures of psychometric 
adequacy suggested that the PAHD correlation matrix was suitable for factor analysis. 
 
Factor analysis revealed four distinct dimensions. Based on the scree plot, it was possible 
to force a two-factor solution which accounted for 45.4% of the variance (Table 3.4). The 
 
 
110 
 
first 10-item factor, BK, included items with loadings greater than 0.47. The scale had a 
reliability of 0.83. Item BK18_R appeared to be factorially complex. While its highest 
loading is on factor 1, it also loads on factor 2. Using a ± .33 as the minimal level of 
practical significance for factor loadings [49], our team could either delete the item from 
the analysis or rewrite it [50]. At this stage of scale development, it was decided to retain 
the item for further investigation. The second 7-item factor, FC, included items with 
loadings greater than 0.50. The scale had a reliability of 0.84. Overall, the factor analysis 
supports the qualitative and quantitative findings. 
 
Discussion 
The PAHD scale was the outcome of a program of research that relied on survey and 
qualitative methods to inform the research team about psychosocial adjustment 
challenges in LS families. The scale was developed from content defining the struggling 
to adjust construct of a theoretical model generated from grounded theory. A four-
member research team developed the scale by generating a large set of potential items, 
refining the items, and validating item content using experts and individuals from 
families with hereditary cancer. 
 
By developing the PAHD from a qualitative data base, the content is steeped in the 
personal experiences of individuals from families with hereditary cancer. Various authors 
argue that instrument item-content generated from qualitative data is more likely to 
capture the experiences of targeted groups [51,52]. It is also argued that clinical tools 
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developed in this manner have better content and face validity and excellent 
psychometric properties [53]. 
 
The current study provides initial evidence to support the psychometric properties of the 
PAHD scale. The pilot study supported the relevancy of item content and logic of the two 
subscale structure. Application of the MAP-R to findings from the larger sample suggests 
that the PAHD has acceptable internal consistency reliability, item-convergent validity 
and item-discriminant validity [44]. Intrascale correlations compared with scale 
Cronbach’s alphas indicate that the two subscales (BK and FC) of the PAHD are 
measuring distinct but interrelated concepts. 
 
The BK scale is intended to capture the subjective perception of individual and family 
burden from knowing about the presence of LS in the family. The mean BK score 
suggests that participants, on average, reported experiencing a little to moderate burden. 
Although no significant differences were observed for carrier and affected status or time 
since genetic testing, women tended to report higher levels of burden than men. Despite 
the limited insight from existing literature on the depth and scope of the long-term 
struggles of individuals living within LS families, several authors acknowledge that their 
complexity is shaped by the interaction of experiential cancer-based knowledge from the 
past and present as well as individual coping styles [14,52,54-57]. Results from the 
current study support previous qualitative findings that a subgroup of individuals 
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experience psychosocial distress in the long-term following confirmation of hereditary 
cancer [39,40]. 
 
The second subscale, FC, is intended to capture the importance of having access to 
resources and family supports in sharing the burden and challenges of hereditary cancer. 
The mean score suggests that respondents, on average, gave high ratings to the presence 
of supportive family structures. Again study findings did not vary based on carrier and 
affected status or time since genetic testing, but women tended to value family supports 
more than men. 
 
The low to moderate correlation between the two subscales support the multidimensional 
nature of the PAHD scale. Given that the correlations between the two scales of the 
PAHD are less than their reliability coefficients, there is evidence of unique reliable 
variance measured by each scale. A major premise of the model from which the PAHD 
was developed is that living in families characterized by open, supportive relationships 
facilitates psychosocial and emotional adjustment and decreases the burden associated 
with the presence of hereditary cancer. Therefore, it was expected that the subscales of 
the PAHD would correlate well with each other. 
 
The findings suggest that individuals with more perceived support from family and 
friends tended to be less burdened from dealing with the challenges posed by hereditary 
cancer in the family. The value of the strength and stability of family support systems for 
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facilitating positive coping and adjustment at the individual and family level is receiving 
increased attention in the research literature on genetic-based diseases [13,52,55,57]. 
 
The results of these analyses provide support for the uniqueness of the PAHD subscales 
and add further credence to its validity. Future studies are needed to determine the scale’s 
potential for monitoring the long-term psychosocial adjustment. 
 
Limitations 
While the initial validation results are promising, there are a number of limitations to 
consider. First the study was cross-sectional and thus it is not possible to evaluate the 
scale’s monitoring capabilities. Second, the use of mixed methods for data collection may 
have influenced the findings. Further, the responders were significantly older than non-
responders thus potentially limiting our knowledge of the experiences of younger 
individuals. Finally, it is also possible that the higher proportion of non-carriers among 
the non-responders may have altered the findings. 
 
Conclusion 
The use of qualitative data to develop the PAHD has produced a scale that is steeped in 
the experiences of individuals and families with hereditary cancer. Initial testing suggests 
that the scale is psychometrically sound and capable of assessing psychosocial 
adjustment. Although study results support other findings reported in the literature, the 
PAHD scale is unique in that it is specific to hereditary cancer. As a clinical monitoring 
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tool for use following genetic testing, it has the potential to identify those who are 
experiencing psychosocial challenges and who may require additional support for optimal 
adjustment. 
 
The PAHD scale has been adapted and is being piloted in a second population with 
hereditary disease. A focus of this pilot is to examine the psychosocial impact of 
arrhythmogenic right ventricular cardiomyopathy (ARVC) on individuals and families 
post-genetic testing. The next stage of research for the project team will focus on 
implementing the PAHD scale in Community Familial Cancer Genetics Clinics 
throughout Newfoundland and Labrador. 
 
Appendix 1 
Psychosocial Adjustment to Hereditary Diseases (PAHD) Scale. 
 
We are interested in the long-term effects of a confirmed HNPCC or Lynch syndrome 
presence in families. Everyone goes through periods of trying to make sense of inner 
feelings about what the future might hold for the self and other family members. Using 
the scale given, you are asked to rate how well each statement reflects your situation 
(Table 3.6). 
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Table 3.6:  Psychosocial Adjustment to Hereditary Diseases (PAHD) Scale 
0 
Not at all 
1 
A little bit 
2 
Moderately 
3 
Quite a bit 
4 
Extremely 
 
1. I think about being a carrier/non-carrier more than I should. 
(BK11_R)……….. 
0 1 2 3 4 
2. I try to be positive about my future health and overall well-being. 
(BK12) ......... 
0 1 2 3 4 
3. It is important for my future health not to dwell on the hereditary link to 
cancer in the family. (BK13) ..................................................................... 
 
0 
 
1 
 
2 
 
3 
 
4 
4. It was hard changing how often I had to screen for cancer. (BK14_R) .... 0 1 2 3 4 
5. It bothers me when others do not accept my carrier/non-carrier status. 
(BK15_R) ........................................................................................ 
0 1 2 3 4 
6. Younger people need to be encouraged to talk about all the cancer in the 
family.  (FC16) ........................................................................................... 
 
0 
 
1 
 
2 
 
3 
 
4 
7. I find it hard dealing with younger family members who get cancer. 
(BK17_R) ............................................................................................... 
0 1 2 3 4 
8. I worry about what the future might hold for younger family members. 
(BK18_R) .................................................................................................. 
0 1 2 3 4 
9. The stress of so much cancer in the family, more so in younger members, 
pulled some of us closer together but pushed others apart. (BK19_R) ...... 
 
0 
 
1 
 
2 
 
3 
 
4 
10. Regular screening for cancer became a constant reminder of my cancer 
risk by being in this family. (BK20_R) ..................................................... 
 
0 
 
1 
 
2 
 
3 
 
4 
 
Some families handle the challenges of a strong cancer presence better than others do. We want to know 
how well individuals in your family support one another. Using the scale given, you are asked to rate how 
well each statement reflects your situation. 
 
11. Feeling supported by family and friends has helped me accept being a 
carrier/non-carrier. (FC21) ........................................................................ 
 
0 
 
1 
 
2 
 
3 
 
4 
12. I find it easy to seek help from family members when I need it. (FC 22) .. 0 1 2 3 4 
13. It is important for everyone to talk openly about the high cancer risk in 
the family. (FC23) ..................................................................................... 
 
0 
 
1 
 
2 
 
3 
 
4 
14. I am concerned that the presence of hereditary cancer has hurt family 
relations.    (BK24_R) ............................................................................... 
 
0 
 
1 
 
2 
 
3 
 
4 
15. I worry that all the suffering and death from cancer is placing too much 
burden on family members. (BK25_R) ..................................................... 
 
0 
 
1 
 
2 
 
3 
 
4 
16. Providing care to other family members with cancer has helped me 
become more accepting of my future. (FC26) ........................................... 
 
0 
 
1 
 
2 
 
3 
 
4 
17. With so much cancer in the family, I worried that something would show 
up on my next screening test. (BK27_R) .................................................. 
 
0 
 
1 
 
2 
 
3 
 
4 
18. When I knew there was a test to see if my family had the cancer gene, I 
was relieved. (FC28) ................................................................................. 
 
0 
 
1 
 
2 
 
3 
 
4 
19. Encouragement and support from family and friends helps one accept the 
need for healthy living and cancer screening. (FC29) ................................ 
 
0 
 
1 
 
2 
 
3 
 
4 
 
Note:   R indicates items to be reverse coded.   BK = Burden of Knowing.         FC = Family Connectedness 
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Background:  Lynch syndrome is a hereditary cancer with confirmed carriers at high risk 
for colorectal (CRC) and extracolonic cancers. The purpose of the current study was to 
develop a greater understanding of the factors influencing decisions about disease 
management post-genetic testing.  
Methods:  The study used a grounded theory approach to data collection and analysis as 
part of a multiphase project examining the psychosocial and behavioral impact of 
predictive DNA testing for Lynch syndrome. Individual and small group interviews were 
conducted with individuals from 10 families with the MSH2 intron 5 splice site mutation 
or exon 8 deletion. The data from confirmed carriers (n = 23) were subjected to re-
analysis to identify key barriers to and/or facilitators of screening and disease 
management.  
Results:  Thematic analysis identified personal, health care provider and health care 
system factors as dominant barriers to and/or facilitators of managing Lynch syndrome. 
Person-centered factors reflect risk perceptions and decision-making, and enduring 
screening/disease management. The perceived knowledge and clinical management skills 
of health care providers also influenced participation in recommended protocols. The 
health care system barriers/facilitators are defined in terms of continuity of care and 
coordination of services among providers.  
Conclusions:  Individuals with Lynch syndrome often encounter multiple barriers to and 
facilitators of disease management that go beyond the individual to the provider and 
health care system levels. The current organization and implementation of health care 
services are inadequate. A coordinated system of local services capable of providing 
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integrated, efficient health care and follow-up, populated by providers with knowledge of 
hereditary cancer, is necessary to maintain optimal health.  
 
Introduction 
The increased use of predictive DNA testing to determine the hereditary basis of familial 
cancer has important implications for cognitive, affective and behavioral outcomes of 
high risk individuals. Investigations into the impact of genetic testing have focused more 
on cognitive and affective responses and less on factors facilitating optimal disease 
management. Our understanding of behavioral responses is a significant gap in the 
research literature.  
 
The most common hereditary colon cancer is Lynch syndrome [1-4] which is an 
autosomal dominant disease accounting for 2-5% of all colorectal cancers (CRCs) 
worldwide [1,5], with geographical clusterings observed [5,6]. A puzzling and 
unexplained feature of the disease is the variable expressivity (differing ages of onset, 
cancer sites) and incomplete penetrance (not all carriers develop the disease) [6,7]. Lynch 
syndrome has a lifetime CRC risk of about 80% [7,8] and is also associated with 
extracolonic cancers of the uterus, ovary, kidney, urinary tract, stomach, biliary tract, 
small intestine and brain [8]. Gynecologic cancers are important for female carriers who 
have a lifetime risk of 40-60% for endometrial and 10-21% for ovarian cancers [4,6].  
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Confirmation of Lynch syndrome means that all family members should undergo 
predictive DNA testing and/or be strongly encouraged to regularly screen. The 
effectiveness of screening in reducing morbidity and mortality from CRC is well 
supported [9,10]. Despite this, there is suboptimal uptake of screening by high-risk 
individuals [11-13]. Wide variability in adherence rates have been reported, with 
colonoscopy screening ranging from 53-100% [11,14-20], transvaginal ultrasonography 
from 69-86% [14,20,21] and endometrial biopsies around 54% [21].  
 
From a clinical management perspective, it is important to know why some high risk 
individuals fail to follow recommended guidelines. Few research inquiries have 
attempted to identify facilitators of, or barriers to, behavioral change following 
confirmation of hereditary disease [22-28]. Merely informing individuals of their cancer 
risk may not motivate behavior change [25] and could possibly impede screening if 
perceived to be uncontrollable [29,30].  
 
Some authors have conjectured that awareness of familial cancer patterns and 
personal/family cancer experiences influence risk perceptions which, in turn, impact 
acceptance of a carrier status and engagement with screening [25-27,30-32]. Other 
authors have used social cognition theory as a template for conceptualizing cognitive and 
emotional factors that impact reactions to predictive DNA testing and, ultimately, 
behavioral responses [25,30,31]. Nevertheless, it remains unclear how risk perceptions 
are shaped by disease-related experiences and impact behavior.  
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High risk individuals are expected to manage their cancer risk [16,21,33]. This can be 
difficult without consensus on the scope, frequency, and age of initiation of screening for 
CRC [4,34-37] and extracolonic cancers [4,34,35,38]. Despite the documented benefits of 
prophylactic interventions, like gynecologic surgeries, for reducing cancer risk [4,34,38], 
these strategies have not been fully integrated into the clinical management of Lynch 
syndrome families.  
 
Health care providers play a key role in encouraging high risk individuals to become 
involved in disease management [4,34,35,39]. It is critical that all providers are 
adequately informed about Lynch syndrome, obtain comprehensive medical and family 
histories [39-41], make referrals to genetics services [4] and recommend appropriate 
screening and management [3,34,36]. However, significant gaps exist in providers 
knowledge [12,42] and many fail to identify at-risk individuals and/or advise them 
appropriately [39,42].  
 
The evidence suggests that the health care system can pose barriers to screening. 
Ineffectual coordination and continuity of care [43], inadequate access to and availability 
of screening/specialty services [44], and variation in provider recommendations [39,43] 
can impede effective clinical management. Currently, there is a paucity of research on 
how individuals interact with the health care system as they adjust to living with a 
confirmed hereditary cancer risk.  
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This article reports on findings derived from a grounded theory study on the psychosocial 
and behavioral impact of genetic testing on individuals at high risk for Lynch syndrome. 
In this paper we focus on how confirmed carriers experience disease management and 
view the quality of interactions with health care providers and the overall health care 
system. We include recommendations on how to improve disease management and 
facilitate quality outcomes.  
 
Methods 
 
Study Design 
A grounded theory study was part of a multiphase project examining the psychosocial 
and behavioral impact of DNA testing for Lynch syndrome. The Human Investigation 
Committee, Memorial University, approved the study protocol.  
 
Grounded theory was used during data collection and analysis [45]. This approach is 
considered appropriate as the focus is not solely on how health threats, diagnostic 
procedures or treatment protocols are experienced, but also on how this information is 
received and assimilated into belief structures, and how this integration becomes a 
stimulant for actions needed to achieve optimal health functioning. The strength of this 
inductive approach is the emphasis placed on identifying and describing the social-
psychological processes grounded in the data emerging from participant interviews [46].  
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Population and Predictive Genetic Testing 
The target population was individuals from high and intermediate risk families registered 
in the Provincial Medical Genetics Program of Newfoundland and Labrador (NL) and 
participating in the larger case control study. Eligible participants for the grounded theory 
study were those living in families with a confirmed MSH2 mutation-the intron 5 splice 
site mutation (942+3A > T) (12 families) or exon 8 deletion (5 families). Details on this 
population have been reported elsewhere [6].  
 
A purposive sample of 39 individuals from 10 families who had completed genetic 
testing and knew their status was selected from the accessible population (N = 276). 
Predictive DNA testing is offered to individuals in high and intermediate risk families. 
Follow-up counseling sessions are held with those interested in testing for known 
mutations. Testing results are normally reported in face-to-face sessions. Follow-up 
letters summarizing the results are forwarded to participants and their physicians. Clinical 
screening programs are adjusted according to test results.  
 
This article focuses on 23 confirmed carriers (14 female, 9 male) from three families with 
the intron 5 splice site mutation and three families with the exon 8 deletion (Table 4.1). 
The mean time from genetic testing to the initial interview was 6.0 (± 2.8) years (range .1 
to 9.6) and age at the first interview was 48.9 (± 13.6) years (range 26 to 78). Thirteen 
participants developed cancer at a mean age of 43 (± 5.8) years (range 33 to 54). 
Significantly, those who had reached the affected stage experienced a total of 27 primary 
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cancers with CRC occurring at least once in 61.5% of the cases. Of the 14 female 
carriers, five developed endometrial cancer (35.7%) and four (28.6%) had prophylactic 
hysterectomies and/or oophorectomies.  
 
Table 4.1:  Participant characteristics (N = 23) 
ID Family Gender Post-GTa Ageb Affected Onset Age Cancer Typesc 
23 1B Female 6.42 57 No --- --- 
24 1B Female 6.42 78 Yes 46 CRC/EC 
25 1B Male 8.50 52 Yes 42 CRC/GA 
26 1B Female 2.42 32 No --- --- 
31 1B Male 7.50 47 Yes 45 CRCx2 
8 1C Male 3.67 28 No --- --- 
22 1C Male 6.50 26 No --- --- 
30 1C Male 7.42 57 No --- --- 
9 2A Female 8.08 41 Yes 39 CRCx2 
32 2A Female 9.58 69 Yes 35 CRCx2/EC/GA/SK 
20 2B Female 9.08 50 Yes 33 EC/BR/VA 
21 2C Male 9.08 50 No --- --- 
10 3A Female 7.00 42 No --- --- 
27 3A Female 8.17 51 Yes 43 Ovarian 
28 3A Male 8.17 43 Yes 45 CRC/DUO 
29 3A Female 7.50 33 No --- --- 
11 3B Male 8.42 76 Yes 39 CRCx2/SK/KD 
4 6 Female 0.75 48 Yes 49 CRC 
19 6 Female 0.08 63 Yes 54 SK 
37 7 Female 3.17 50 Yes 46 KD/EC 
38 7 Male 3.08 46 No --- --- 
34 8 Female 2.83 43 Yes 40 EC 
36 8 Female 3.75 42 No --- --- 
Note. Families 1B to 3B have the intron 5 mutation and families 6 to 8 have the exon 8 deletion. The use of A, B or C after the 
family number denotes separate nuclear families within a particular extended family. 
a Years since genetic testing. 
b Age at first interview. 
c CRC = colorectal; EC = endometrial; GA = gastric; SK = skin; BR = breast; VA = vaginal; 
KD = kidney; DUO = duodenal. 
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Procedure 
After initial contact, interested individuals were forwarded a cover letter, brief study 
summary and consent form, and re-contacted to schedule interviews. Following 
informed, written consent, two interviewers (principal investigator and research assistant) 
conducted 60 to 90 minute interviews with participants. Individual or small group 
interviews (immediate family only) took place in participants' homes or conference 
rooms. Open-ended questions elicited commentary on experiences with cancer in the 
family (first awareness of hereditary link, perceived personal risk, screening motivation) 
and genetic testing (decision-making, counseling experiences, reaction to status, 
understanding implications, impact on family). Additional questions evolved from the 
thematic content analysis (adjusting to carrier status, screening experiences, health care 
service needs). A second interview provided participants with an opportunity to comment 
upon and confirm their interpretive summaries. Information from the second interview 
also helped the research team augment gaps in the data, and the conceptual categories and 
properties of the emerging substantive theory.  
 
Data Analysis 
Data analysis proceeded in several phases. First, interviews were transcribed verbatim 
and perused independently by a three-member team. The focus was on interpreting the 
meaning of words and sentences through reading and re-reading the text, and assigning 
substantive codes to recurrent themes. Team discussions focused on achieving consensus 
on emerging themes. Second, mid-way through data collection, interviewing was 
 
 
134 
 
temporarily stopped and the constant-comparative method of analysis applied to the data 
sets by two members working independently. The objective was to identify relationships 
between and among substantive codes. As potential category relationships were tested 
within the data, a substantive theory began to emerge.  
 
Third, in-depth analysis of the first 18 transcripts revealed a family context (i.e., 
experiential base and degree of burden and sense of resilience), differences between 
carriers and non-carriers of Lynch syndrome (views of screening protocols and timelines 
to diagnosis, coping approaches to short/long term prognosis, implications for children) 
and differences between affected and unaffected carriers (intensity of reactions to cancer 
onset/recurrences). The focus shifted to purposive selection of an additional 14 carriers 
from family groupings with many (n = 9) having reached the affected stage. This 
approach to subject selection facilitated confirmation of the substantive codes and 
refinement of their properties.  
 
In the later stages of analysis, length of time since discovery of the family-based gene 
mutation and the availability of and actual involvement in genetic testing surfaced as 
potential influencing factors on individual and family perceptions. The decision was 
made to sample additional individuals to determine the importance of time. Data 
collection continued (n = 7) until the research team was confident that the experiences of 
this group would not alter existing properties or categories. At the final step, the data and 
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resulting theory were examined by an independent consultant to enhance credibility and 
accuracy. This resulted in a more parsimonious and refined set of themes and codes.  
 
Results 
Data analysis revealed several personal, provider and health system barriers to and/or 
facilitators of effective disease management. Risk perceptions and acceptance of the 
genetic link to cancer influenced individuals' ability to adjust to their carrier status and 
accept recommended regimes. Despite the importance of risk perceptions and acceptance, 
interactions with the health care system and providers clearly affected overall adjustment.  
 
Person-Centered Barriers/Facilitators 
The most important personal factors were emotional and psychosocial states, physical 
health status, prior experiences with cancer screening and/or treatment, and accepting the 
need for prophylactic interventions. These factors are categorized as risk perceptions and 
decision-making, and enduring screening/disease management.  
 
Risk Perceptions and Decision-Making 
Risk perceptions play a crucial role in motivating individuals to become involved in 
disease management. A meaningful balance must be forged between the cognitive and 
emotional spheres for decision-making. Full engagement seems to be highly contingent 
upon emotionally accepting potential threats to the self and understanding the benefits of 
ongoing monitoring and timely interventions.  
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Participants spoke about the emotional and physical challenges of living with Lynch 
syndrome. Despite understanding the importance of following recommended protocols, 
the burden of dealing with this disease can be overwhelming.  
 
Like I can sit here and say to you, 'Oh yeah, all the knowledge in the world, it's 
great to know. But look at it from the human part of it, your own self going 
through this every single day'. Every time someone goes to a doctor, my crowd is 
like, 'Who is next, right?' It gets to you after a while. [I10, Fam3A]  
 
All participants echoed the importance of screening while being ever mindful of the 
challenge of living with high cancer risk. Only one participant had not engaged in cancer 
screening following a positive genetic test result. However, not all of the participants 
were participating in the full scope of cancer screening and/or adhering to recommended 
intervals. Oscillating cognitive and emotional forces impinge on individuals' willingness 
to become fully involved in the process.  
 
Although some participants had misgivings about knowing their status, these doubts soon 
subsided when screening detected cancer. Several individuals alluded to the potential 
benefits of regular screening.  
 
I started seeing [gynecologist] on a regular basis. I was constantly being screened; 
it [uterine cancer] was picked up. I had the Pap smear and then the endometrial 
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biopsy and both of that came back abnormal. It [cancer] was just in the early 
stages. [I37, Fam7]  
 
Participants also recognized the need to accept and assume responsibility for healthy 
living and self-monitoring for signs and symptoms of an impending illness. Some 
perceived this as critical for disease management.  
 
Since I found out that I have the gene, I try to eat a little better and ... exercise a 
little better. You watch for things and you're a little more conscious of the things 
you're putting in your body. [I26, Fam1B]  
 
How well individuals adjusted to the burden of the disease had important implications for 
their willingness to follow recommended guidelines. Everyone who accepted having 
Lynch syndrome recognized the benefits of disease management. For some, the 
motivation to do so was enhanced following early cancer detection.  
 
Enduring Screening and Disease Management 
Participants often experienced conflicting emotions about knowing what had to be done, 
wanting to do it and actually doing it. For many, scheduling appointments and waiting for 
diagnostic test results became physically draining, time consuming, and burdensome.  
Successful adjustment seemed highly contingent upon living as normal a life as possible 
without being constantly reminded of cancer risk. The anxiety and worry associated with 
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the probability of cancer detection created emotional barriers that impeded actions, 
forcing some to use "time out" periods.  
 
I'm after falling off the wagon a bit, where I've had a couple of surgeries. ... I 
couldn't do one test because I was doing something else. ...Then after one of the 
surgeries, I guess you kind of reach your tolerance level. It was a conscious 
decision. ...I just had to give it up for a while. [I9, Fam2A]  
 
Participants relayed stories of endurance and perseverance. Although the full scope of 
physical and emotional difficulties was individual specific and time dependent, many 
commented on the challenges of regular screening. Even when highly motivated, the 
emotional strain of upcoming procedures can be quite burdensome especially when prior 
experiences evoke unpleasant memories: "It's just as well to tell the truth, I cry. I'm 
weeks before thinking about it and I'm dreading it. I'm dreading the day that the test will 
come." [I37, Fam7]  
 
For many participants, the type and frequency of screening protocols and recommended 
prophylactic interventions increased with evolving knowledge and/or emerging cancer 
patterns within the family. The increasing demands often became a struggle: "It 
[screening] is cumulative and I find more and more. I don't dwell on it, but it's changing 
and I find I'm really, really sick of having to have this..." [I34, Fam8]  
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Ongoing disease management requires adequate resources to support everyday living. 
The significance of this for any one person can be influenced by their financial status, 
family responsibilities and employment history, among others. For many, accessing 
appropriate cancer care involves having the means and willingness to travel outside of 
their communities, taking time off work and/or having adequate support to deal with 
family responsibilities. Practical issues are important because they may interfere with 
one's willingness and ability to access recommended screening/treatment.  
 
I'm a year in the hole on my sick leave here now. So if I got a flu or anything like 
that, I can't just stay home. Every appointment [for diagnostic tests], where I'm 
running to town is over so many hours ... it is sick leave. Then I had surgeries 
where you take off six weeks. [I9, Fam2A]  
 
When early stage cancer is identified, physical and psychological benefits occur 
immediately following treatment. These benefits may not be so obvious for individuals 
asked to consider prophylactic surgery in the absence of signs and symptoms of disease. 
Female family members are encouraged to have prophylactic hysterectomy and bilateral 
salpingo-oophorectomy because of their high risk for endometrial and ovarian cancer, 
especially when parents or sisters have had these cancers. In the current study, four 
women had prophylactic surgery without having symptoms of disease whereas another 
two had hysterectomies for benign gynecological disease.  
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The "present" for many participants reflects a story of survivorship and endurance. It was 
apparent from listening to their stories that the burden of screening/treatment sometimes 
became a deterrent to continuance. This burden was augmented or lessened by the scope 
of family and work responsibilities.  
 
Provider-Centered Barriers/Facilitators 
The perceived knowledge and skills of health care providers surfaced as key factors 
facilitating or impeding participation in regular screening and disease management. 
Participants wanted to receive care from physicians/specialists familiar with their family 
cancer history. Trust seemed to increase when physicians were intimately aware of the 
family history and acknowledged the importance of monitoring high risk cancer sites.  
 
When you get a doctor like that [open and engaging] it means something because 
you don't feel like you're just a number, like they know you personally. They 
seem like they care and you don't come across too many like that. I felt like a 
number for so long. [I27, Fam3A]  
 
Most disconcerting for participants was the perceived tendency for some physicians to 
discount age of onset of first cancers in families as a benchmark for screening initiation 
and follow-up. When physicians failed to do this, participants distrusted their knowledge: 
"The problem is they are young and because they are young the doctors aren't testing 
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[screening] them properly for bowel cancer. Not testing them early enough. They're not 
realizing that even now after all this." [I23, Fam1B] 
 
Integral to effective monitoring is having knowledge of the natural history of the disease. 
Following encounters with physicians who seemed to have limited understanding of 
Lynch syndrome, some participants felt the need to become better informed and share 
this knowledge with them.  
 
Every time I go to him [physician] I say, 'Now do you know that these lesions are 
sometimes flat? ...Don't look for bumps. Look for these flat lesions which are the 
Lynch II'. Even now I don't know if he hears me. Because they'll always talk 
about removing polyps and I don't know if that's set out enough in the literature. 
[I20, Fam2B]  
 
Similar concerns were expressed about physicians not perceived to be attentive enough to 
the extracolonic cancers.  
 
It would be nice if we knew it was being monitored and we were all getting the 
proper checks. But not only just for bowel. I mean they do a colonoscopy, that's 
not going to show if you have anything in your ovaries or kidneys or anywhere 
else. [I23, Fam1B]  
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From a clinical management perspective, participants assessed physicians in terms of the 
completeness of medical care and quality of communications. Medical care was 
evaluated by the thoroughness of history taking and physical examinations. If unsure 
about a physician's approach, participants felt the need to enlighten them.  
 
Unless you can tell a doctor what is wrong with you he can't see through you and 
know, unless you recognize symptoms yourself. Gone are the days when ... they 
[physicians] do a complete physical and chest x-ray. ...They don't look at it 
[cancer] as coming from a history. [I32, Fam2A]  
 
Quality of communications was defined in terms of effective interpersonal skills. 
Participants wanted providers who were sincere and took the time to facilitate 
understanding. Some commented on the limited communication of an informative nature 
and the lack of perceived support: "When I go for a colonoscopy, it's the quicker you're in 
and out the better. It's no such thing as sit down for any discussion. We got no support 
system." [I25, Fam1B]. Other participants presented a contrasting perspective.  
 
When they found things that he [specialist] has been suspicious about, he showed 
me the pictures and he sits down. 'This is what we are going to do'. ...So he's 
always been very informative. ...I appreciate that, I want that honesty. ...So I can 
be actively involved with what happens to me. [I21, Fam2C]  
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In essence, living with Lynch syndrome is an independent journey that requires being 
attentive to physical changes, appreciative of their implications for future health, and 
assertive about receiving care from knowledgeable, caring providers.  
 
Health Care System Barriers/Facilitators 
Continuity of care at the provider and system levels seemed to pose great difficulty for 
participants. Continuity of care is dependent upon continuous information flow (disease 
and person-focused), strategic coordination of services (complementary and timely), and 
accessing a consistent provider mix over time. Restricted continuity of care can play 
havoc with successful disease management.  
 
Especially vital is ongoing collaboration among primary and specialty care sectors during 
the planning and delivery of services. As the number of diagnostic procedures and 
potential cancer sites increase, there is a concomitant increase in the number of specialists 
involved in providing care and, thus, the greater potential for inconsistencies in 
recommended screening intervals. A couple of participants voiced their frustrations 
following interactions with different aspects of the health care system: "But my family 
doctor argued that it [colonoscopy] should be every year. I feel it should be done every 
year. Every three years the [specialist] wants it done." [I38, Fam7]; "I haven't been done 
since two years ago. That extra six months could mean a lot to me. So what am I 
supposed to do?" [I27, Fam3A]  
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Study participants were of the opinion that poor communication among providers could 
be detrimental to a person's well-being, quality of life and, ultimately, long-term survival. 
An important message conveyed is that greater consensus is needed on acceptable 
screening intervals and targets, especially in families with a higher than usual penetrance 
rate for CRC and associated cancers.  
 
Participant comments also conveyed a vivid picture of limited organization and 
coordination of health care. Individuals confront challenges navigating the health care 
system particularly when having to deal with different institutions and 
physicians/specialists. At times, this requires a tenacious, persistent approach and a 
working knowledge of the system.  
 
Every six months I ... have the ultrasound done. ...Then I have to make an 
appointment to see the specialist ... for what? It is a negative ultrasound. Then 
you're supposed to ... get another ultrasound but they can't get an appointment set 
up that far in advance. ...then you need a requisition. [I9, Fam2A]  
 
Everyone echoed the need for a more coordinated approach that lessens the demands on 
personal time and coping resources. One participant commented thus, "I would like to 
have one stop shopping. It seems like I am running around doing all this and I don't want 
this. I don't need this." [I4, Fam6]  
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Timely access to services can become a major liability, with delays especially upsetting 
for individuals subject to heightened uncertainty and worry. Participants suggested that 
carriers should be given priority access to screening and specialty services.  
 
After I had my operation [for colon cancer] I phoned up for another appointment 
[with specialist] and they told me that it could be another six months before I get 
in and my year was up then right. ...So I phoned the doctor that operated on me 
and I got in within two weeks. ...I was frightened right. [I31, Fam1B]  
 
Despite being aware of requisite health care services, system challenges often prevented 
participants from 'being ahead of the game'. Especially critical is a coordinated system of 
care which provides timely access and follow-up. Without adequate resources, 
individuals are at greater risk to be burdened by the disease.  
 
Discussion 
The current study highlights the many personal, provider and system level barriers to and 
facilitators of engaging in effective disease management. Study findings suggest that 
participants seem to be well-informed about Lynch syndrome, have accurate risk 
perceptions and acknowledge the benefits of regular screening. Nevertheless, the 
interaction of the emotional and physical burden of disease management with the 
practical demands of everyday living (family and work) and provider and health care 
system challenges may also significantly influence behavior.  
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Only a few studies have stressed that the behavioral impact of genetic testing is an 
important area for research [2,22,23,28]. Most studies have focused on psychological 
outcomes as opposed to potential barriers to and facilitators of informed decision-making 
concerning screening/treatment regimes. The current study provides informative insight 
into some of these factors. The findings highlight the physical and psycho-emotional 
obstacles (worries/concerns about potential test results/prophylactic interventions, 
intensity and scope of screening, preparation for and experiences with diagnostic 
procedures, scheduling issues) that can increase the burden of disease management. Other 
researchers have noted that physical and psychological barriers can add to the burden of 
screening, and pose deterrents to regular participation [11,14,20,32,47].  
 
The importance of disease-related experiences for facilitating adjustment and determining 
the appropriateness and relevancy of healthy behaviors is not new. This finding supports, 
in part, the argument put forth by others that behavioral responses are a function of 
perceived risk which is influenced by health threat representations that continuously 
evolve in response to experiences with the disease in the self and/or others [25,30,31].  
 
The current study also supports how interactions with health care providers can impact 
the overall burden of Lynch syndrome. Ratings of the quality of provider care are a 
function of perceived knowledge levels and clinical management approaches. A growing 
body of evidence supports the significant role played by physicians and other providers in 
 
 
147 
 
improving adherence in this population [13,16,33,34,43]. It is therefore important that all 
providers become informed about current screening and treatment protocols [16,35,48].  
Several authors confirm the controversy over suitable time intervals for colonoscopy 
[34,35,40,41] and the variable attention given to extracolonic cancers [17,38]. These 
inconsistencies are worrisome. Previous research has found that those at increased risk 
for CRC receive insufficient information on screening intervals, risk assessment and 
procedures, and inadequate emotional support between diagnostic tests [20,43]. This 
situation not only impedes development of best practice guidelines but also creates 
problems for physicians involved in disease management [49,50].  
 
Experiences with and reactions to encounters with the health care system can impede 
effective disease management. Our findings suggest that existing counseling and disease 
management resources are inadequate to meet the demands that follow predictive DNA 
testing. An important source of dissatisfaction is gaining timely access to needed 
services. Ineffective coordination of diagnostic, treatment and specialists' appointments 
creates unnecessary delays, enhances worry, and propels some to distance themselves 
from the whole process. It is apparent that referral protocols need to be simplified and 
more coordinated. Some authors have highlighted the need for a single service [12] or a 
multidisciplinary team comprised of providers committed to following evidence-
informed clinical guidelines [12,20,38,39,50].  
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Our research illuminates the possibility of new roles for health care providers in cancer 
genetics. In Canada there is no national registry, as provided in some smaller countries. 
In the province of NL four regional health authorities (RHAs) are responsible for 
delivering a range of health care services in hospitals, clinics and community health 
programs within their respective geographic areas. Recently, genetics clinics have been 
established in three of these RHAs. These clinics will be linked to the Provincial Medical 
Genetics Program which will integrate clinical care with the evaluation of interventions 
directed toward improving clinical outcomes. Other researchers concur that familial 
cancer registries and genetics service centers are perceived to be effective mechanisms 
for facilitating quality outcomes [12,34,35].  
 
Despite the limitations of a small sample size and inherent biases in having participants 
recall how they experienced and reacted to specific events and situations, the findings do 
provide practical insight into barriers and facilitators that may be individual, provider 
and/or system based.  
 
Conclusions and Policy Implications 
This study has further illuminated the psychosocial and behavioral impact of predictive 
DNA testing for Lynch syndrome. Many participants were confronted with serious issues 
in managing their disease. These issues require preventive strategies to help maintain 
optimal health and a reasonable quality of life. What is important for families is the 
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presence of providers with the necessary knowledge and skill base and a coordinated 
system of local services capable of providing integrated health care and timely follow-up.  
 
Ideally, genetic counseling should facilitate the adoption of appropriate, lifelong disease 
management strategies. In light of the current findings, genetic counselors may need to 
assess the family and socio-cultural context of hereditary cancer [24] and its potential 
influence on decision-making. It is also necessary to explore the emotional aspects of 
living with cancer risk so that the burden of the disease can be lessened.  
 
Importantly, Lynch syndrome has significant implications for public health policy [4]. 
The ultimate plan should be to provide resources that enable individuals in high risk 
families to develop a strong sense of resilience and maintain a balanced screening 
schedule. In particular, this cohort requires timely and appropriate health care services, 
including:  
• A critical mass of genetic counselors to provide timely services to high risk 
families before, during and following genetic testing.  
• Service providers to coordinate and streamline diverse screening and treatment 
resources. 
• Health care providers, especially primary care physicians, informed about the risk 
of cancer within families and reinforcing the importance of maintaining 
recommended screening and initiating referrals to appropriate specialists.  
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• Clinical monitoring tools designed to evaluate the impact of predictive testing and 
the ongoing psychosocial and behavioral adjustment to living in families with 
hereditary cancer.  
 
The current uncoordinated, physician dependent organization of screening for individuals 
with Lynch syndrome in Canada is inadequate. Given the incidence and prevalence of 
these hereditary cancers and the clinical benefits of screening, there is a critical need to 
provide integrated health care and timely follow-up in a manner that facilitates navigation 
of and access to the health system.  
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General Discussion 
The final chapter provides a summary discussion of the findings, implications for clinical 
practice, research and policy, and limitations of the research. This program of research 
was designed to investigate the long-term psychosocial and behavioral adjustment to 
living in families with LS. Confirmation of hereditary cancer through predictive DNA 
testing requires adjustment on several levels. Individuals and families experience variant 
and evolving psychosocial and emotional states in response to being a carrier or non-
carrier. Carriers are recommended to follow highly targeted surveillance and 
management strategies necessitating adjustment on a behavioral level. Adjustment to the 
presence of hereditary cancer is best described as an evolving state that ebbs and flows in 
response to changing personal and family experiences in the management of long-term 
cancer risk and emergence of cancer in the self and/or others. Personal and/or family 
experiences can facilitate or impede adjustment.  
 
To understand adjustment following genetic testing for LS, it is necessary to examine a 
complex set of interacting factors that are individual, family and health care system-
based. Biesecker and Erby (2008) [1] highlight the importance of viewing adjustment as a 
multidimensional construct, with many potential interacting factors altering its 
presentation at any point in time. Other authors suggest that psychological and emotional 
responses to genetic testing information are influenced by individual, familial, social and 
medical factors [2]. 
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Since the identification of the mismatch repair genes 20 years ago, significant research 
has focused on the psychosocial implications of genetic testing for LS. Less research has 
been focused on living with and managing cancer risk in the long-term, how those at risk 
adjust behaviorally and how experiences with the health care system impact disease 
management. Given the lifelong surveillance required for those with LS, it is imperative 
that facilitators of and barriers to recommended screening and treatment be identified. It 
is also critical that health care providers be able to identify those at risk for poor 
adjustment following confirmation of LS so that strategies promoting quality outcomes 
can be implemented. 
 
The struggling to adjust construct of the substantive theory from the qualitative study 
was used to develop monitoring tools capable of assessing adjustment. Findings from the 
first paper presented in Chapter 2 examining the psychosocial and emotional implications 
of living in families with LS indicate that carriers, affected and unaffected with cancer, 
and non-carriers oscillated between positive and negative feeling states. While most were 
able to adjust psychosocially to cancer risk in the self and/or others, some were burdened 
by this reality and struggled to adjust. Importantly, our findings provide new knowledge 
on the long-term adjustment of carriers who developed cancer, an area recently identified 
by others as lacking research [3]. Some of the participants in our study had two or more 
cancer episodes resulting in the experiential knowledge that LS is often a challenging, 
evolving entity that brings much uncertainty to individuals and families. 
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The presence of LS in a family can involve diverse, complex experiences that can occur 
concurrently at any point in time [4]. While some members may be coming to terms with 
being at risk, others may be undergoing genetic testing and/or cancer screening. Other 
members may be adapting to genetic test results, facing a cancer diagnosis, dealing with 
cancer treatment, managing other co-morbidities and/or experiencing the loss of a family 
member. Those with a confirmed mutation may be confronting issues with the testing 
and/or screening of children. Our findings support these ever-changing and cumulative 
situations within a family. These experiences can present individual and cumulative 
challenges, impact psychosocial responses [4] and result in continued uncertainty over the 
lifespan [5].  
 
Our qualitative findings indicating that a subgroup of carriers and non-carriers experience 
psychosocial and emotional distress in living with LS has important implications for the 
management of those with hereditary cancer syndromes. Assisting individuals and 
families to adjust to hereditary cancer requires understanding of the potential 
psychosocial issues that could arise during the genetic testing process and beyond [6]. 
Knowledge of the complex and, often unpredictable, issues that individuals and families 
have to confront over time following confirmation of LS can assist health care providers 
in intervening in a timely manner. It is also important to understand how personal or 
family psychosocial factors impact health behaviors that are deemed essential in reducing 
morbidity and mortality associated with LS. Other researchers have suggested that 
psychological well-being is linked to clinically relevant outcomes in LS [4]. 
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Our findings also suggest that hereditary cancer has implications for the entire family. 
Participants valued having a supportive family environment, access to resources and open 
communications to help manage the many challenges imposed by LS. While most 
families were able to communicate openly about their cancer risk, be there for each other 
and receive support, some were challenged in dealing with the burdens associated with 
hereditary cancer. These findings suggest that health care interventions for those at risk 
should extend beyond the individual to the family, a finding supported by others [7,8]. 
However, those providing care should also be aware of the individuality of family 
member’s responses to the confirmation of hereditary cancer [9] and anticipate similar 
and disparate reactions among members of the same family. It is also crucial to recognize 
that individual adjustment to LS can be significantly shaped by the family context and 
dynamics [8,9]. 
 
In summary, it was apparent from the interviews in the qualitative study that individuals 
living in LS families experience a wide range of emotional, psychological and social 
issues that have important implications for their health and quality of life. These findings 
and the inability of previously used standardized instruments to consistently identify 
those experiencing adjustment difficulties led the research team to use the qualitative data 
base to design clinical monitoring tools. It is anticipated that these tools be used to inform 
the delivery of cancer genetics services.  
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As discussed in paper two in Chapter 3 the PAHD scale was developed from content 
defining the struggling to adjust construct of a theoretical model generated from 
grounded theory and tested in 243 carriers and non-carriers of LS. Using a descriptive 
correlational design the PAHD scale was psychometrically tested using the 
Multitrait/Multi-Item Analysis Program-Revised (MAP-R) [10], a method used by others 
[11,12]. 
 
The PAHD, steeped in the experiences of those living in families with LS, was found to 
be a psychometrically sound scale that is capable of assessing psychosocial adjustment. 
Clinical monitoring tools are needed to evaluate the impact of genetic testing and the 
ongoing psychosocial and behavioral adjustment to living in families with hereditary 
diseases. Currently, instruments commonly used in research on the psychosocial 
implications of genetic testing have focused on identifying symptoms such as depression, 
anxiety and/or cancer specific distress. This approach can be limiting in that the 
instruments are not specific to hereditary diseases and may not capture the unique 
impacts brought on by genetic knowledge and cancer risk. Others conclude that screening 
tools specific to hereditary diseases, used during the genetic testing process, can help 
genetic service providers identify those who may require interventions and/or follow-up 
[7]. 
 
Results from the development and preliminary testing of the PAHD support the 
qualitative findings that a subgroup of individuals experienced psychosocial distress in 
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the long-term and were burdened by the presence of LS. In fact, our findings indicated 
that over one third of the 243 participants experienced personal and family burden 
associated with adjusting to LS. Approximately two thirds of the participants experienced 
moderate to extreme difficulty in dealing with young people who developed cancer with 
non-carriers experiencing significantly more burden than carriers. The majority of 
carriers and non-carriers had moderate to extreme worry in relation to the future of 
younger family members. These findings suggest that individuals living in LS families 
may need support in dealing with the impact on younger family members. Overall, the 
findings provide support for the qualitative study and insight regarding the burdensome 
situations that LS families may have to endure. Previous research on LS indicates that 
parents are concerned about how their children will be impacted [9,13] and worry about 
children getting cancer at a young age [9]. 
 
Results also indicated that nearly two thirds of participants in the quantitative study 
perceived that screening tests heightened their worry about cancer. Some of the 
participants in the qualitative study also reported worrying about the possibility of finding 
cancer during their screening/surveillance tests. Other researchers suggest that fear of 
finding cancer [14,15] and worry may influence screening behaviors [16]. 
 
The quantitative findings also highlight the significance of the family’s supportive 
structure, resources and openness in dealing with and managing LS. The majority of 
participants perceived that access to resources and having open communications were 
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very important in dealing with LS, a finding confirming our qualitative results. These 
findings also provide further evidence that openly discussing the presence of hereditary 
cancer in the family is highly valued [14,17] and plays a significant role in managing 
cancer risk [9] Previous research supports the influence of family resources and a positive 
family environment on the psychological well-being of individuals in LS families [17-
20]. 
 
The results reinforce the need to identify those who may be at risk for psychosocial and 
emotional challenges in adjusting to LS. Therefore, the next step is to assess the clinical 
utility of the PAHD. It is proposed that the tool be used within the context of providing 
genetic testing services. It is planned that individuals seeking genetic counseling and 
testing for LS will be administered the PAHD. It is anticipated that the scale will assist in 
identifying those who may be at risk for poor psychosocial adjustment following 
confirmation of LS in the family. Identifying those who are experiencing or may be at 
risk for adjustment difficulties can facilitate the provision of health care services that 
focus on specific individual and family needs. Knowledge gleaned from the PAHD could 
also assist genetics personnel to plan and implement appropriate interventions and 
follow-up care.  
 
Secondary analysis of the struggling to adjust construct in the qualitative study also 
indicated a second dominant theme, one focusing on behavioral adjustment to LS in the 
short- and long-term. The third paper in Chapter 4 focused on behavioral implications for 
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confirmed carriers. To date, investigations on the impact of genetic testing and living in 
families with LS have concentrated more on psychosocial and emotional implications and 
less on behavioral outcomes. Given the CRC cancer risks and mounting evidence on the 
development of extracolonic cancers in those with specific mutations [21], investigations 
on behavioral adjustment are critical. The benefits of cancer screening in the LS 
population have been documented [22,23] and published guidelines for clinical 
management have recently been updated [21]. Research on the effectiveness of 
surveillance for CRC and extracolonic cancers is expanding as researchers and clinicians 
attempt to propose best practice guidelines that are based on sound evidence. While 
colorectal surveillance is highly recommended and deemed effective, screening for select 
extracolonic cancers is suggested despite their lack of documented effectiveness [21,24]. 
 
Importantly, individuals with a confirmed LS mutation should be provided with screening 
recommendations and encouraged to comply [3]. While the research base on screening 
behaviors and adherence rates following confirmation of LS is expanding [25-30], 
minimal research has focused on identifying factors which could impact an individual’s 
long-term adherence and behavioral adjustment. The qualitative findings discussed in 
Chapter 4 highlight the many personal, health care provider and system level barriers to 
and facilitators of screening and disease management in LS. Our findings are unique in 
that this is the first study, to our knowledge, to comprehensively investigate personal, 
health care provider and system factors that can impact the overall burden of LS. Study 
findings suggest that a number of factors can individually impact or interact to influence 
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behavioral outcomes. While some participants were able to overcome barriers to 
effectively managing LS, many were confronted with serious issues and struggled to 
adhere to recommended guidelines. Health care providers and the system should support 
individual and family efforts to manage LS. Therefore, the findings have significant 
implications for the clinical management of individuals and families with LS. 
 
The struggling to adjust construct also provided data for the development and preliminary 
testing of a second adjustment scale for confirmed carriers. The Behavioral Adjustment 
to Hereditary Diseases (BAHD) scale addresses the perceived burden of 
screening/treatment, perceptions of quality health care, management of children who may 
be at risk and perceptions of what is needed to promote effective management of LS. 
Further analysis is currently being conducted on this scale and a publication on its 
development is planned. It is proposed that the clinical utility of the scale will be assessed 
within the context of genetic testing for individuals with a confirmed gene mutation for 
LS. 
 
Clinical Practice Implications 
In this section the implications for clinical practice, policy and research will be 
addressed. It is acknowledged that, given the relationship between clinical practice, 
policy and research, there are implications presented which could be applicable to all 
three areas. In the past decade information about the identification and management of 
LS has grown exponentially. With cancer genetics services being offered in primary care 
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and increased availability of genetic testing, health care providers must have the 
appropriate knowledge and skills to assist individuals and families with effective disease 
management. Findings from the studies in this dissertation have practice implications that 
serve to enhance the provision of genetic counseling, genetic testing and overall clinical 
management of individuals and families with LS.  
 
The variation and complexity of individual and family experiences with LS necessitates a 
tailored approach to the provision of genetic services. Consideration must be given to all 
aspects of the disease, including the experiential impact of living in these families and the 
genetic testing process, as well as the short- and long-term adjustment to living with LS 
and the concomitant formal and informal support requirements. It is also recognized that 
some individuals living in LS families may have a lifelong need for support from genetics 
personnel [3].  
 
Rapid developments in gene discovery and genetic testing for hereditary diseases are 
placing demands on genetic counselor services that may exceed supply [31]. It is also 
suggested that in hereditary cancer syndromes where individuals are often cared for by 
multiple health care providers, other professionals may play a role in meeting 
psychological support needs [31]. Other researchers suggest training a larger number of 
mental health professionals to work in cancer genetics clinics [3]. Our qualitative 
findings also support the possibility of new roles for health care professionals such as 
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nurses in cancer genetics [32]. Nurses can be educated to provide quality health care 
services and ongoing support to individuals and families. 
 
Genetics personnel need to be cognizant of the variant levels of awareness of cancer in 
the family and the closeness of relatives affected as this influences risk perceptions, 
comprehension, acceptance and emotional readiness to become informed of one’s risk. 
The impact of the familial social environment on adjustment to hereditary cancer is also 
receiving increased attention. The quality of family relations is also significant in shaping 
perceptions of risk and managing LS. Assessing family functioning in relation to the 
impact of familial cancer events can help illuminate an individual’s level of awareness 
and acceptance of high-risk status. Knowledge gained from this assessment can help 
genetics personnel identify those with strong and weak family support structures. 
Families with supportive structures and openness to giving/receiving support suggest the 
presence of sufficient resources to help deal with the challenges of living with LS. 
However, those with limited family connectedness may be in need of additional 
interventions to minimize adjustment difficulties.  
 
The use of the PAHD, as a clinical monitoring tool in cancer genetics services, can 
provide baseline and periodic information on individuals and their families at critical 
junctures in the delivery of services. It may assist genetics personnel to identify those 
who are experiencing or may be at risk for psychosocial and emotional challenges 
following confirmation of LS. This can enable genetics personnel to plan and implement 
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interventions that are tailored to the needs of the individual and family. It is conjectured 
that the PAHD can identify those who are feeling burdened by the presence of LS and are 
struggling to manage their disease effectively in the short- and long-term. It is also 
conjectured that the tool can identify those who may lack a supportive family structure in 
dealing with the challenges posed by LS. Recognizing those who may be experiencing 
challenges on a psychosocial and emotional level can facilitate supportive interventions. 
It is also suggested that those who are supported emotionally and psychosocially in 
managing LS may comply with recommended protocols and benefit from life-saving 
cancer surveillance. 
 
LS is under diagnosed in many families [33]. Therefore, primary care physicians and 
nurse practitioners informed about the risk of cancer within high-risk families, are needed 
to identify those at risk, reinforce recommended screening and initiate referrals to 
appropriate specialists. They need to be cognizant of the features of LS, be aware of the 
extracolonic cancers associated with the syndrome and be able to do an extensive family 
history on the patient. These clinicians play an important role in identifying high-risk 
individuals, encouraging adherence to recommended screening and providing follow-up 
care after a cancer diagnosis has been made [34,35]. 
 
Individuals who are confirmed carriers may encounter challenges when faced with 
lifelong screening and/or treatment, particularly when there are cumulative effects 
resulting from the practical demands of daily living. These individuals may need 
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additional psychosocial and emotional support in dealing with these challenges and 
assistance in navigating the health care system to ensure access and continuity. 
Individuals may also need help in obtaining accurate, evidence-based information, 
accessing recommended screening and communicating results and information to others. 
Health care providers with a skill base in cancer genetics have what is required to assist 
individuals and families in promoting effective disease management. 
 
What is critically important is the provision of accurate and consistent cancer screening 
information (i.e., type, interval and age of initiation) to individuals and families. It is 
possible that failing to strictly adhere to current screening recommendations, particularly 
for CRC, can result in increased mortality. Therefore, it is essential that clinicians have 
current knowledge of screening and treatment protocols and assist individuals to maintain 
screening regimes. Although screening recommendations for select extracolonic cancers 
are not supported with evidence, it is vital that clinicians be aware of the types of cancers 
in the family and those associated with specific LS gene mutations. Information on 
cancers more commonly associated with select mutations also needs to be clearly 
communicated to individuals and families. If screening for other types of cancers is being 
carried out it is also important to fully inform individuals about the benefits and 
limitations of such screening [21].  Of significance for female carriers is the incidence of 
endometrial and ovarian cancer and the lack of effective screening tests for early 
detection. This situation raises concerns about whether low detection rates can impact a 
woman’s psychosocial adjustment, particularly if they are fully informed about the 
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benefits and limitations of current screening for these cancers. Low detection rates for 
various cancers may also be associated with inexperienced health care providers who do 
not have sufficient knowledge of LS cancer types and presentation.  
 
The incidence of extracolonic cancers in LS also illuminates the need for individuals to 
be vigilant in monitoring for any health changes and to seek health care immediately. 
However, timely access to health care providers and the system must be readily available 
and able to respond when health changes are suspected and/or diagnosed. As highlighted 
in the qualitative study, access to timely screening, surveillance and treatment and 
continuity of care were identified as barriers to effective disease management. The 
important role of familial cancer registries in the management and  
 
Assessing for a family history of cancer in FCCTX families is also crucial given the lack 
of distinctive morphological features [36]. One study in NL found that of 29 non-LS 
families who fulfilled the Amsterdam I criteria, 28 of them met the criteria for FCCTX 
[37]. Given the many individuals with a family history of CRC who have unknown 
mutations, it is imperative that those working in primary care be aware of the possibilities 
beyond LS and provide evidence-based cancer screening/surveillance recommendations. 
 
Policy Implications 
The research findings have revealed the far-reaching psychosocial, emotional and 
behavioral implications of genetic testing and living with LS. These findings have 
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implications that serve to enhance the provision of genetic counseling, genetic testing and 
overall management of individuals and families with LS. From a policy perspective, the 
ultimate plan should be to provide a coordinated system of resources capable of 
providing integrated health care and follow-up in a manner that promotes optimal health 
functioning and overall well-being. These resources should extend well beyond the initial 
genetic testing event and encompass all aspects of effective disease management. The 
findings illuminate the need for health care resources that are responsive to the needs of 
individuals and families with hereditary cancer. There is a need for adequate resources to 
identify those with LS as well as assist individuals in adopting and adhering to lifelong 
cancer screening and treatment protocols. 
 
In particular, this population requires a number of timely and appropriate health care 
services. A multidisciplinary approach to the provision of services has been proposed, 
including a single service to coordinate screening [38]. In the province of Newfoundland 
and Labrador an initiative is being pilot tested to have Community Familial Cancer 
Genetics Clinics within the regional health authorities. Ideally, these clinics would 
provide the full gamut of genetics, informational and support services as well as 
coordinate recommended screening for at-risk individuals. Other researchers report that 
familial cancer registries and genetics service centers are perceived to be effective 
mechanisms for facilitating quality outcomes [38]. Since the first polyposis registry 
established in the United Kingdom in 1925, many familial cancer registries have been 
established worldwide, including those specific to LS [39]. These registries have an 
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important role in the ongoing management of LS with many coordinating screening 
programs and other aspects of multidisciplinary care [39]. Some authors propose that all 
individuals with LS be managed within the context of a registry [40]. Registries also 
provide other benefits such as patient-focused care and a database for conducting 
research [41]. 
 
At the first step, these clinics require a critical mass of genetic counselors to provide 
timely services to at-risk individuals and families about LS before, during and following 
genetic testing. Health care providers, knowledgeable about the natural history of LS, its 
disease trajectory and management, must also be available to coordinate and streamline 
diverse health care services. Within these clinics, a multidisciplinary approach is needed 
to ensure that individuals’ screening/surveillance protocols are maintained and/or 
modified based on evidence and the evolving family cancer history [38]. 
 
Finally, the interface of the environment, epigenetics and colorectal cancer must be given 
increased attention. Traditional epidemiological research has focused on the roles of 
genetic, environmental and lifestyle factors in the development of CRC [42]. This body 
of knowledge continues to support the premise that LS cancers are influenced by 
environmental and lifestyle as well as genetic factors. A recent review outlined studies 
investigating the influence of factors such as meat intake, smoking, alcohol, body mass 
index (BMI) and dietary fibre/fruit on cancer development in LS. The authors of the 
review conclude that smoking and a higher BMI increase the risk of developing 
 
 
176 
 
adenomas and CRC in LS [21], a finding supported by others [3]. A Western diet has also 
been implicated in an increased risk of CRC [3]. Recently, one study found that aspirin 
significantly reduced the risk of CRC in LS [43].  
 
Research on epigenetics and LS is also providing evidence to explain the development of 
cancer in those who do not have a pathogenic mutation [44]. Molecular epidemiology is 
expanding at a rapid pace and focusing on interactions between genetics and 
environmental, dietary and lifestyle factors in carcinogenesis [42]. Given the presence of 
unknown mutations, environmental complexities, variability in the health care 
environment and inadequate sensitivity and specificity of screening tests for extracolonic 
cancers in LS, continued attention to these areas is paramount.  
 
Research Implications 
The findings presented in the dissertation have implications for future research. At the 
first step, the clinical utility of the PAHD and its ability to identify those who may be 
experiencing adjustment challenges in living with LS must be evaluated. Adaptation of 
the PAHD for use with other hereditary diseases is also anticipated. Currently, it has been 
modified for a pilot test in a population with arrhythmogenic right ventricular 
cardiomyopathy (ARVC). A pilot study of the instrument in FCCTX families is also 
planned. 
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Given the importance of adhering to recommended cancer surveillance protocols, it is 
prudent to examine whether there is a relationship between psychosocial implications and 
behavioral outcomes in LS. Currently, there is an initiative underway to merge data from 
the psychometric study outlined in chapter 3 and data from a cancer screening study in 
the same population. The cancer screening data base provides information on the actual 
screening practices of both carriers and non-carriers. It is conjectured that those who are 
experiencing high levels of emotional and psychosocial burden in managing LS may 
experience challenges with engaging in regular screening. Identifying those who are 
experiencing such difficulties would facilitate the development of supportive 
interventions. 
 
The psychosocial and behavioral implications of living in families with FCCTX should 
also be examined. These are families who have multiple members with CRC across 
several generations but with an unknown genetic etiology [45]. Due to the lack of 
psychosocial research efforts in this population, it would be important to qualitatively 
explore how individuals in these families adjust to the high incidence of cancer in the 
family, perceive barriers to and facilitators of screening and view their support needs. 
Information gleaned from the qualitative data can then be used to modify the PAHD for 
use in these families. 
 
Another area for research is with groups who have received less attention [3]. These 
groups include cultural minorities and adult children of those with a confirmed mutation. 
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Our research findings unveiled a number of carrier concerns related to the management 
of children, particularly in terms of genetic testing and screening. As these new 
generations at risk come of age, it is essential that research findings articulate their 
support and information needs and understand the long-term perspective of living in LS 
families [3]. 
 
Limitations 
The research studies presented in this dissertation have a number of limitations. First of 
all, many types of selection bias (e.g., ascertainment, volunteer, non-response and loss to 
follow up) can be present in studies of genetic diseases [46]. In all phases of the 
quantitative and qualitative studies presented here, the participants were considered to be 
high-risk based on a combination of clinical and Amsterdam criteria. The use of 
restrictive criteria to identify those at risk could have caused an ascertainment bias 
towards families with multiple members who had cancer and a more severe phenotype 
[46].  
 
It is also conjectured that self-selection bias may have been a limiting factor in that a 
number of respondents participated in all phases of the research. One of the inclusion 
criteria for all of the studies was that participants had to have participated in predictive 
DNA testing. It is possible that those who volunteered to engage in genetic testing and 
participate in research were more motivated than those who refused and may not be 
representative of all individuals living in families with LS [46]. 
 
 
179 
 
Given that the quantitative studies in both phases of the research were cross-sectional and 
involved questionnaires, it is possible that those who did not respond were more 
burdened by the presence of LS in the family. In the larger quantitative study on the 
development and preliminary testing of the PAHD, the responders were significantly 
older than the non-responders thus potentially limiting our knowledge of the experiences 
of younger individuals who are living in families with LS. Further, the higher proportion 
of non-responders among the non-carrier cohort may have also impacted the findings. 
The findings may have also been limited by the use of mixed methods for data collection. 
Also, the use of a cross-sectional design precluded the evaluation of the PAHD’s 
monitoring capabilities.  
 
The use of small sample sizes for the qualitative phase of the research may have limited 
the generalizability of the findings. Further, the results may not be generalizable to ethnic 
minority individuals. Finally, the inherent biases in having participants recall how they 
experienced genetic testing and/or responded to specific situations/events may have 
impacted the findings. 
 
Conclusion 
The research findings have revealed the far-reaching psychosocial, emotional and 
behavioral implications of living in families with LS. Lynch syndrome is a lifelong, 
evolving disease that requires individuals and families to adjust on many levels. This 
adjustment should be monitored at various junctures during the genetic testing process 
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and beyond receipt of results. To assess psychosocial adjustment, the PAHD scale was 
developed from a qualitative data base. Preliminary testing of the scale indicates that it is 
psychometrically sound. The subscales and overall scale structure were validated and it 
was determined that the scale met Likert scaling assumptions. The next step is to test the 
clinical utility of the scale in cancer genetics services and assess its ability to identify 
individuals and families who may require therapeutic interventions. 
 
The current organization and provision of cancer genetics and health care services to LS 
families are inadequate. The barriers identified in the current research must be eliminated 
so that individuals can access and engage in evidence-based protocols. To ensure that 
individuals and families are effectively managing LS, a system of integrated and 
coordinated services should be implemented. Community genetics clinics should be 
resourced so that genetic counseling, genetic testing, psychosocial support, coordination 
of screening, timely follow-up care and assistance in navigating the health care system 
can be provided to those living in families with hereditary cancer. 
 
In conclusion, clinicians and families need to think longitudinally about the course of LS 
with normative landmark transitions and constantly changing demands. This will help 
individuals and families achieve a sense of resilience and maintain an optimal quality of 
life in living with and managing LS. 
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Appendix A: Amsterdam Criteria 
 
Amsterdam Criteria I 
There should be at least three relatives with colorectal cancer 
- one relative should be a first-degree relative of the other two 
- at least two successive generations should be affected  
- at least one tumour should be diagnosed before age 50 
- familial adenomatous polyposis should be excluded 
- tumours should be verified by histopathological examination 
 
Amsterdam Criteria II 
There should be at least three relatives with colorectal cancer or with a Lynch syndrome-
associated cancer: cancer of the endometrium, small bowel, ureter or renal pelvis 
- one relative should be a first-degree relative of the other two 
- at least two successive generations should be affected  
- at least one tumour should be diagnosed before age 50 
- familial adenomatous polyposis should be excluded in the colorectal cancer case if any 
- tumours should be verified by histopathological examination 
 
Vasen HF, Watson P, Mecklin JP, Lynch HT: New clinical criteria for hereditary 
nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International 
Collaborative Group on HNPCC. Gastroenterology 1999, 116:1453-1456. 
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Appendix B 
Human Investigation Committee Approval and Consent  
Protocol:  Phase I (Quantitative) 
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Appendix C 
Sampling Plan – Phase I (Quantitative and Qualitative) 
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Appendix C: Flow Chart of Sampling Plan - Phase I (Quantitative and Qualitative) 
  
Eligible (N = 276) 
(NCCFR) 
Contacted (N = 201) Unable to Contact (N= 75) 
46 (incomplete information) 
29 (no response) 
Agreed (N =188) Refused (N = 13) 
Quantitative Survey I 
Returned Survey (N = 120) 
 
Qualitative Stage 1 (N=32) 
Intron 5 (6/12 families): n=27 
Exon 8 (2/5 families): n=5 
 
Stage 2-Exon 8 (n=7) 
Exon 8 (2/5 families) 
 
Total Qualitative Sample (N=39) 
Intron 5 (6/12 families) 
Exon 8 (3/5 families) 
 
Total Exon 8 (N=12) 
Exon 8 (3/5 families) 
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Appendix D 
Human Investigation Committee Approval and Consent  
Protocol: Phase I (Qualitative) 
 
  






 
 
196 
 
 
 
 
 
 
 
 
 
 
Appendix E 
Research Proposals Approval Committee: 
Phase I (Qualitative) 
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Appendix F 
Human Investigation Committee Approval and Consent  
Protocol: Phase II (Quantitative) 
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Appendix G 
Research Proposals Approval Committee: 
Phase II (Quantitative) 
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Appendix H 
Sampling Plan – Phase II (Quantitative) 
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Appendix H: Flow Chart of Sampling Plan – Phase II (Quantitative) 
 Pilot Project  
February –June 2008 
179 potential participants 
149 possible participants 
Exempt participants (30): Deceased, refused, unable to contact, 
not involved in genetic testing, status unknown, obligate 
carriers, HNPCC cancer < 50 years, cognitive impairment, 
recent loss in family/cancer diagnosis in the self, no contact 
 
33 excluded because they could not be reached or had died 
since last contact for research purposes 
7 refused to participate 
Psychometric Pilot Project 
Final count = 75 (75/120= 63%) 
45 carriers and 30 non-carriers 
Continuation of Project: 
June 2008 to July 2010 
354 potential participants from the 
Colorectal Cancer Screening database 
265 potential participants 
103 additional potential respondents identified 
from other studies or family members of those 
participating in the current psychometric study (n 
=52) + individuals with other HNPCC mutations 
(25 exon 4-16 deletion, 22 MLH1, 4 MSH6) 
109 potential participants 
120 potential participants 
109 surveys mailed in February and 
March 2008 
Decision made to recruit 11 additional non-carriers 
Exempt participants (192): Deceased, refused, unable to 
contact, not involved in genetic testing, status unknown, 
obligate carriers, HNPCC < 50 years, cognitive 
impairment, recent loss in family/cancer diagnosis in the 
self, no contact information. 
162 potential participants 
Only 19 completed questionnaires from non-carriers 
received 
12 refused to participate 
Returned surveys: 151 
151/253= (59.7%) 
Contactable Potential Participants 
N=392 
373 agreed to review study materials 
243/373= 65.1% 
130 survey packages remain in circulation 
Pilot n = 28 
Larger project n =102 
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Appendix I 
Hereditary Diseases: Psychosocial and Behavioral  
Adjustment Scale 
 









